<?xml version="1.0" ?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.3 20210610//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">elife</journal-id>
<journal-id journal-id-type="publisher-id">eLife</journal-id>
<journal-title-group>
<journal-title>eLife</journal-title>
</journal-title-group>
<issn publication-format="electronic" pub-type="epub">2050-084X</issn>
<publisher>
<publisher-name>eLife Sciences Publications, Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">109534</article-id>
<article-id pub-id-type="doi">10.7554/eLife.109534</article-id>
<article-id pub-id-type="doi" specific-use="version">10.7554/eLife.109534.1</article-id>
<article-version-alternatives>
<article-version article-version-type="publication-state">reviewed preprint</article-version>
<article-version article-version-type="preprint-version">1.2</article-version>
</article-version-alternatives>
<article-categories><subj-group subj-group-type="heading">
<subject>Medicine</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Computational and Systems Biology</subject>
</subj-group>
</article-categories><title-group>
<article-title>Global molecular landscape of early MASLD progression in obesity</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Zhao</surname>
<given-names>Qing</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1441-1295</contrib-id>
<name>
<surname>De Nardo</surname>
<given-names>William</given-names>
</name>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0009-0003-5579-0492</contrib-id>
<name>
<surname>Wang</surname>
<given-names>Ruoyu</given-names>
</name>
<xref ref-type="aff" rid="a5">5</xref>
<xref ref-type="aff" rid="a10">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhong</surname>
<given-names>Yi</given-names>
</name>
<xref ref-type="aff" rid="a8">8</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6771-3721</contrib-id>
<name>
<surname>Keles</surname>
<given-names>Umur</given-names>
</name>
<xref ref-type="aff" rid="a10">10</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0009-0002-5066-6663</contrib-id>
<name>
<surname>Sakalauskaite</surname>
<given-names>Gabrielé</given-names>
</name>
<xref ref-type="aff" rid="a10">10</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6552-0929</contrib-id>
<name>
<surname>Zhao</surname>
<given-names>Li Na</given-names>
</name>
<xref ref-type="aff" rid="a10">10</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0009-0009-9256-2118</contrib-id>
<name>
<surname>Tay</surname>
<given-names>Huiyi</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Youhanna</surname>
<given-names>Sonia</given-names>
</name>
<xref ref-type="aff" rid="a8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yan</surname>
<given-names>Mengchao</given-names>
</name>
<xref ref-type="aff" rid="a9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xie</surname>
<given-names>Ye</given-names>
</name>
<xref ref-type="aff" rid="a9">9</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7816-9602</contrib-id>
<name>
<surname>Kim</surname>
<given-names>Youngrae</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0655-5050</contrib-id>
<name>
<surname>Lee</surname>
<given-names>Sungdong</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0009-0009-0241-9079</contrib-id>
<name>
<surname>Lim</surname>
<given-names>Rachel Liyu</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3891-1494</contrib-id>
<name>
<surname>Teo</surname>
<given-names>Guoshou</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Narayanaswamy</surname>
<given-names>Pradeep</given-names>
</name>
<xref ref-type="aff" rid="a7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Burton</surname>
<given-names>Paul R</given-names>
</name>
<xref ref-type="aff" rid="a6">6</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1140-6204</contrib-id>
<name>
<surname>Lauschke</surname>
<given-names>Volker M</given-names>
</name>
<xref ref-type="aff" rid="a8">8</xref>
<xref ref-type="aff" rid="a9">9</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6687-3088</contrib-id>
<name>
<surname>Choi</surname>
<given-names>Hyungwon</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
<email>hyung_won_choi@nus.edu.sg</email>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Watt</surname>
<given-names>Matthew J</given-names>
</name>
<xref ref-type="aff" rid="a4">4</xref>
<email>matt.watt@unimelb.edu.au</email>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7247-7591</contrib-id>
<name>
<surname>Kaldis</surname>
<given-names>Philipp</given-names>
</name>
<xref ref-type="aff" rid="a10">10</xref>
<xref ref-type="author-notes" rid="n1">&amp;</xref>
<email>philipp.kaldis@med.lu.se</email>
</contrib>
<aff id="a1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01tgyzw49</institution-id><institution>Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore</institution></institution-wrap>, <city>Singapore</city>, <country country="SG">Singapore</country></aff>
<aff id="a2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01tgyzw49</institution-id><institution>Singapore Lipidomics Incubator, Life Sciences Institute, National University of Singapore</institution></institution-wrap>, <city>Singapore</city>, <country country="SG">Singapore</country></aff>
    <aff id="a3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01tgyzw49</institution-id><institution>Cardiovascular &amp; Metabolic Disease Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore</institution></institution-wrap>, <city>Singapore</city>, <country country="SG">Singapore</country></aff>
    <aff id="a4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01ej9dk98</institution-id><institution>Department of Anatomy and Physiology, School of Biomedical Sciences, Faculty of Medicine Dentistry and Health Sciences, University of Melbourne</institution></institution-wrap>, <city>Melbourne</city>, <country country="AU">Australia</country></aff>
    <aff id="a5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01ffek432</institution-id><institution>Department of Hepatology, The First Hospital of Hunan University of Chinese Medicine</institution></institution-wrap>, <city>Changsha</city>, <country country="CN">China</country></aff>
    <aff id="a6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01wddqe20</institution-id><institution>Department of Surgery, School of Translational Medicine, Monash University, Australia and Bariatric Unit, Department of General Surgery, The Alfred Hospital</institution></institution-wrap>, <city>Melbourne</city>, <country country="AU">Australia</country></aff>
    <aff id="a7"><label>7</label><institution>SCIEX, R&amp;D</institution>, <city>Singapore</city>, <country country="SG">Singapore</country></aff>
    <aff id="a8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/056d84691</institution-id><institution>Department of Physiology and Pharmacology and Centre of Molecular Medicine, Karolinska Institutet</institution></institution-wrap>, <city>Stockholm</city>, <country country="SE">Sweden</country></aff>
    <aff id="a9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02pnjnj33</institution-id><institution>Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology</institution></institution-wrap>, <city>Stuttgart</city>, <country country="DE">Germany</country></aff>
<aff id="a10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/012a77v79</institution-id><institution>Department of Clinical Sciences Malmö and Lund University Diabetes Centre (LUDC), Lund University, Clinical Research Centre (CRC)</institution></institution-wrap>, <city>Malmö</city>, <country country="SE">Sweden</country></aff>
</contrib-group>
<contrib-group content-type="section">
<contrib contrib-type="editor">
<name>
<surname>Seldin</surname>
<given-names>Marcus M</given-names>
</name>
<role>Reviewing Editor</role>
<aff>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/04gyf1771</institution-id><institution>University of California, Irvine</institution>
</institution-wrap>
<city>Irvine</city>
<country country="US">United States</country>
</aff>
</contrib>
<contrib contrib-type="senior_editor">
<name>
<surname>Choi</surname>
<given-names>Murim</given-names>
</name>
<role>Senior Editor</role>
<aff>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/04h9pn542</institution-id><institution>Seoul National University</institution>
</institution-wrap>
<city>Seoul</city>
<country country="KR">Republic of Korea</country>
</aff>
</contrib>
</contrib-group>
<author-notes>
<fn id="n1" fn-type="others"><label>&amp;</label><p>Lead Contact</p></fn>
<fn fn-type="coi-statement"><p>Competing interests: VML is co-founder, CEO and shareholder of HepaPredict AB, as well as co-founder and shareholder of Shanghai Hepo Biotechnology Ltd. All other authors declare no conflict of interest.</p></fn>
</author-notes>
<pub-date date-type="original-publication" iso-8601-date="2025-12-15">
<day>15</day>
<month>12</month>
<year>2025</year>
</pub-date>
<volume>14</volume>
<elocation-id>RP109534</elocation-id>
<history>
<date date-type="sent-for-review" iso-8601-date="2025-11-12">
<day>12</day>
<month>11</month>
<year>2025</year>
</date>
</history>
<pub-history>
<event>
<event-desc>Preprint posted</event-desc>
<date date-type="preprint" iso-8601-date="2025-10-09">
<day>09</day>
<month>10</month>
<year>2025</year>
</date>
<self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2025.01.13.632747"/>
</event>
</pub-history>
<permissions>
<copyright-statement>© 2025, Zhao et al</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Zhao et al</copyright-holder>
<ali:free_to_read/>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="elife-preprint-109534-v1.pdf"/>
<abstract>
<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is often asymptomatic early on but can progress to irreversible conditions like cirrhosis. Due to limited access to human liver biopsies, systematic and integrative molecular resources remain scarce. In this study, we performed transcriptomic analyses on liver and metabolomic analyses on liver and plasma samples from morbidly obese individuals without liver pathology or at early-stage MASLD. While, the plasma metabolomic profile did not fully mirror liver histological features, dual-omics integration of liver samples revealed significantly remodeled lipid and amino acid metabolism pathways. Integrative network analysis uncoupled metabolic remodeling and gene expression as independent features of hepatic steatosis and fibrosis progression, respectively. Notably, GTPases and their regulators emerged as a novel class of genes linked to early liver fibrosis. This study offers a detailed molecular landscape of early MASLD in obesity and highlights potential targets of obesity-linked liver fibrosis.</p>
</abstract>
<abstract abstract-type="graphical">
<title>Graphical abstract</title>
<fig id="ufig1" position="float" orientation="portrait" fig-type="figure">
<graphic xlink:href="632747v2_ufig1.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords</title>
<kwd>Metabolic dysfunction-associated steatotic liver disease</kwd>
<kwd>Lipid metabolism</kwd>
<kwd>Fibrosis</kwd>
<kwd>GTPase signaling</kwd>
<kwd>Obesity</kwd>
</kwd-group>
<funding-group>
<award-group id="par-1">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004359</institution-id>
<institution>Vetenskapsrådet (VR)</institution>
</institution-wrap>
</funding-source>
<award-id>2021-01331</award-id>
<principal-award-recipient>
<name>
<surname>Zhao</surname>
<given-names>Qing</given-names>
</name>
</principal-award-recipient>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta specific-use="meta-only">
<meta-name>publishing-route</meta-name>
<meta-value>prc</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<fn-group content-type="summary-of-updates">
<title>Summary of Updates:</title>
<fn fn-type="update"><p>This version has been revised based on reviewers comments, including improved clarity and additional data.</p></fn>
</fn-group>
</notes>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease, affecting over 30% of adults worldwide <sup><xref ref-type="bibr" rid="c1">1</xref></sup>. The prevalence of MASLD is closely associated with the epidemic of obesity, with an estimated 75% prevalence among individuals with obesity compared to 32% in the general population <sup><xref ref-type="bibr" rid="c2">2</xref></sup>. As liver manifestation of the metabolic syndrome, MASLD can cause, and is also caused by concurrent metabolic abnormalities commonly seen in obese individuals, such as insulin resistance, diabetes, dyslipidemia, and hypertension <sup><xref ref-type="bibr" rid="c3">3</xref>, <xref ref-type="bibr" rid="c4">4</xref></sup>.</p>
<p>Early stages of MASLD are characterized by hepatic steatosis, which is the excessive deposition of triacylglycerol (TAG) rich lipid droplets (LD) within the liver parenchyma and is usually reversible. However, in a subset of patients, the disease can develop into inflammatory and ballooning stages termed metabolic dysfunction-associated steatohepatitis (MASH), a more severe form of the disease with an increased incidence and severity of fibrosis. Fibrosis can be present at any stage of the MASLD spectrum of disease and at each stage is increasingly associated with treatment complications, liver-related and overall mortality <sup><xref ref-type="bibr" rid="c5">5</xref>–<xref ref-type="bibr" rid="c7">7</xref></sup>. Unresolved fibrosis can progress to end-stage diseases including hepatic cirrhosis, and hepatocellular carcinoma, lethal malignancies with limited treatment options <sup><xref ref-type="bibr" rid="c8">8</xref>, <xref ref-type="bibr" rid="c9">9</xref></sup>.</p>
<p>Metabolic dysfunction is a primary feature and contributor of MASLD pathogenesis <sup><xref ref-type="bibr" rid="c10">10</xref></sup>. Hepatic steatosis is often accompanied by increased glucose production <sup><xref ref-type="bibr" rid="c11">11</xref></sup>, elevated de novo lipogenesis <sup><xref ref-type="bibr" rid="c12">12</xref></sup>, and disrupted cholesterol homeostasis <sup><xref ref-type="bibr" rid="c13">13</xref></sup>. Mitochondrial respiration is adaptively upregulated to prevent lipid accumulation in obesity <sup><xref ref-type="bibr" rid="c14">14</xref></sup>, but with MASLD progression, mitochondria can become dysfunctional and exacerbate metabolic dysregulation <sup><xref ref-type="bibr" rid="c15">15</xref></sup>. These interconnected metabolic phenotypes form the basis for the development of MASLD <sup><xref ref-type="bibr" rid="c16">16</xref>, <xref ref-type="bibr" rid="c17">17</xref></sup>. Recent advancements in metabolomics have greatly enhanced the understanding of the molecular systems biology of MASLD <sup><xref ref-type="bibr" rid="c18">18</xref>, <xref ref-type="bibr" rid="c19">19</xref></sup>, however, few studies have combined such analysis with transcriptomics to provide integrative insights into disease pathogenesis in humans.</p>
<p><underline>Fibrosis is the only histological feature of MASLD</underline> associated with liver-related mortality and morbidity <sup><xref ref-type="bibr" rid="c20">20</xref></sup>. In the injured liver, damaged and apoptotic hepatocytes modulate the crosstalk between hepatocytes, liver macrophages (Kupffer cells), and hepatic stellate cells (HSCs) by releasing fibrogenic cytokines (e.g., TGF-β) and activating multiple signaling pathways <sup><xref ref-type="bibr" rid="c21">21</xref>, <xref ref-type="bibr" rid="c22">22</xref></sup>. As a result of the multicellular response, HSCs transdifferentiate into active, collagen-producing myofibroblasts, driving fibrogenesis and the excessive deposition of extracellular matrix (ECM) <sup><xref ref-type="bibr" rid="c22">22</xref></sup>. Since fibrosis is a key prognostic marker of MASLD progression, the shift from steatosis to fibrosis marks a critical point in the disease, offering a key opportunity for intervention to prevent further progression <sup><xref ref-type="bibr" rid="c23">23</xref></sup>. Despite the availability of certain guidelines for clinical management of MASLD <sup><xref ref-type="bibr" rid="c24">24</xref>, <xref ref-type="bibr" rid="c25">25</xref></sup>, the molecular and metabolic changes underpinning the key transitions driving disease progression in the context of obesity remain poorly understood. This poses a challenge to early disease management and prevention.</p>
<p>In this study, we generated a comprehensive map of gene expression and metabolomic profiles to delineate the molecular events associated with early-stage MASLD progression in obesity. Using this multi-omic resource, we focused our investigation on key molecular changes associated with (a) the transition from obesity with normal hepatic histology to MASLD and (b) the onset of liver fibrosis. Our data reveal distinct molecular signatures underlying steatosis and fibrosis progression, offering a detailed molecular portrait of the liver in early MASLD and highlighting potential therapeutic targets for reversing fibrosis at initial stages.</p>
</sec>
<sec id="s2">
<title>Results</title>
<sec id="s2a">
<title>Overview of the study</title>
<p>We analyzed samples from 109 obese individuals recruited before bariatric surgery at The Avenue, Cabrini, or Alfred Hospitals in Melbourne, Australia (<xref rid="tbl1" ref-type="table">Table 1</xref> and Table S1). Following the exclusion criteria described in Materials and Methods, 33 individuals lacked histological abnormalities (no MASLD) and 76 had MASLD (<xref rid="fig1" ref-type="fig">Figure 1A</xref>). Notably, 83 individuals (76%) were females in this cohort. Most individuals with obesity were in the early disease stages, with 74 individuals (68%) displaying grade 0-1 steatosis and 83 (76%) grade 0-1 fibrosis. Hepatic inflammation and ballooning were mild, with 9 cases exhibiting grade 2 or higher inflammation and only one case showing grade 2 ballooning (<xref rid="fig1" ref-type="fig">Figure 1B</xref> and <xref rid="tbl1" ref-type="table">Table 1</xref>). In clinical tests, MASLD patients displayed worse liver function (higher alanine transaminase (ALT)/aspartate aminotransferase (AST) ratio and gamma-glutamyl transpeptidase (GGT) levels), higher non-high-density (HDL) lipoprotein cholesterol and blood triglyceride levels, higher C-peptide, and insulin resistance compared to those with ‘No MASLD’ (<xref rid="tbl1" ref-type="table">Table 1</xref>, p &lt; 0.05), confirming correct classification. Liver fibrosis was strongly correlated with insulin resistance, while steatosis grades were most correlated with the levels of plasma lipids (<xref rid="fig1" ref-type="fig">Figure 1C</xref>).</p>
<fig id="fig1" position="float" orientation="portrait" fig-type="figure">
<label>Figure 1:</label>
<caption><title>Study overview.</title>
<p>(A) The overall study design. (B) Alluvial diagram of patient composition of groupings across liver histological features. (C) Relationship between clinical test results and stages of liver histological features. Node size was determined by –log10(p value) in ANOVA tests. Color indicates the significance degree [–log10(p value)] and the direction of change from early to late stages. (D) Number of metabolites analyzed in the liver and plasma. (E-F) Principal component analysis of liver metabolome, plasma metabolome, and liver transcriptome. (G) Disease spectra covered in this cohort and comparison to two published datasets.</p></caption>
<graphic xlink:href="632747v2_fig1.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<table-wrap id="tbl1" orientation="portrait" position="float">
<label>Table 1.</label>
<caption><title>Patient characteristics</title></caption>
<graphic xlink:href="632747v2_tbl1.tif" mimetype="image" mime-subtype="tiff"/>
</table-wrap>
<p>We performed parallel transcriptomic profiling of liver slices and metabolomic analysis of liver and plasma samples (see Materials and Methods). Untargeted metabolomics (covering polar &amp; non-polar metabolites including lipids) enabled semi-quantification of 1104 liver and 962 plasma metabolites, respectively (<xref rid="fig1" ref-type="fig">Figure 1D</xref>). Plasma urea and creatinine levels from untargeted metabolomics closely correlated with clinical assays (Figure S1A), supporting data reliability. Principal component analysis (PCA) revealed distinct clustering of the liver metabolome by MASLD status, but not in plasma (<xref rid="fig1" ref-type="fig">Figure 1E</xref>). The liver transcriptome was modestly separated between individuals with and without MASLD along the main principal components (<xref rid="fig1" ref-type="fig">Figure 1F</xref>), indicating that transcriptional programs may be shaped by both MASLD histological progression and confounding metabolic and biological processes in obese individuals (Table S2).</p>
<p>As steatosis and fibrosis are the key histological features of MASLD, our statistical analyses focused on identifying molecular determinants linearly associated with their progression (Table S3-5). Models were adjusted for patient characteristics (age, sex, and BMI) and type 2 diabetes, the latter due to its differing prevalence across disease groups (<xref rid="tbl1" ref-type="table">Table 1</xref>). Moreover, we compared our transcriptomic data with those from two additional published cohorts: the Virginia cohort (VA cohort, GSE130970) <sup><xref ref-type="bibr" rid="c26">26</xref></sup> with a disease spectrum comparable to that of our study, and the European cohort (EU cohort, GSE135251) <sup><xref ref-type="bibr" rid="c27">27</xref>, <xref ref-type="bibr" rid="c28">28</xref></sup> with a broader spectrum of the disease covering advanced MASLD pathologies (<xref rid="fig1" ref-type="fig">Figure 1G</xref>).</p>
</sec>
<sec id="s2b">
<title>Global investigation of the metabolome in obese MASLD patients</title>
<p>As expected, the liver metabolome was extensively remodeled in individuals with MASLD. Steatosis is the primary histological feature linked to liver metabolome, with 206 metabolites showing significant positive associations and 242 showing negative associations (q &lt; 0.05, <xref rid="fig2" ref-type="fig">Figure 2A</xref> and Figure S1B). For example, we observed higher levels of glycerolipids (GLs, e.g. TAGs, diacylglycerols [DAGs]) and lower levels of membrane lipid classes, especially glycerophospholipids (GPLs) (<xref rid="fig2" ref-type="fig">Figure 2A-B</xref> and Figure S1B). Specifically, TAGs with 0 to 5 double bonds in the fatty acyl chains were positively associated with the histological outcomes, whereas TAGs containing at least one polyunsaturated fatty acid (PUFA) chain (e.g. number of double bonds &gt; 5) were negatively associated with disease progression, particularly with steatosis (Figure S1C). Our findings are likely the results of increased de novo lipogenesis and elevated hepatotoxicity associated with saturated fatty acids <sup><xref ref-type="bibr" rid="c29">29</xref>, <xref ref-type="bibr" rid="c30">30</xref></sup>.</p>
<fig id="fig2" position="float" orientation="portrait" fig-type="figure">
<label>Figure 2:</label>
<caption><title>Hepatic and circulating metabolome in obese individuals with MASLD.</title>
<p>(A) Number of metabolites in each class that were significantly associated with histological features in the liver (q value &lt; 0.05). Metabolite classes with at least 5 metabolites with significance are shown in the plot. (B) Associations between steatosis grades and lipid species in each lipid class. Dots were colored by double bond numbers (left) and carbon numbers (right) of lipid species, respectively. (C) Partial correlation network of the plasma metabolome and clinical covariates. Node size reflects the degree of connectivity, with larger nodes indicating connections to a greater number of metabolite nodes. (D) Heatmaps for pairwise analysis between plasma lipid classes and clinical variables. Linear regression analysis was performed for numerical variables, while logistic regression was conducted for binary variables. Significance values refer to –log10(p value)*sign(coefficients) from regression models. (E) Comparisons of liver metabolome and plasma metabolome regarding their associations with liver steatosis and fibrosis.</p></caption>
<graphic xlink:href="632747v2_fig2.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>The plasma metabolome displayed limited associations with the histological features (<xref rid="fig2" ref-type="fig">Figure 2A</xref>), with statistically significant associations primarily with steatosis, such as TAGs (q value &lt; 0.05, n = 22) and ether-linked TAG (TAG-O, q value &lt; 0.05, n = 8) species. To better interpret the plasma metabolome data, we performed partial correlation network analysis to assess the associations among circulating metabolites, clinical variables, and hepatic histology in individuals with obesity <sup><xref ref-type="bibr" rid="c31">31</xref></sup>. The network demonstrates the highest connectivity of plasma metabolites with clinical variables and fewer connections with hepatic histology features (<xref rid="fig2" ref-type="fig">Figure 2C</xref>). This implies that plasma metabolome largely reflects other metabolic conditions such as kidney function, dyslipidemia, and insulin resistance rather than hepatic features. Most plasma lipid classes were correlated with blood lipoprotein cholesterol levels (<xref rid="fig2" ref-type="fig">Figure 2D</xref>). However, in the context of obesity, blood lipoprotein levels did not show strong correlation with MASLD progression (Figure S2), indicating that their broad impact on plasma metabolome may mask the signals from hepatic abnormalities.</p>
<p>We next compared steatosis- and fibrosis-associated metabolite changes in the liver and plasma (<xref rid="fig2" ref-type="fig">Figure 2E</xref>). Plasma GLs exhibited similar but weaker associations with liver steatosis compared to hepatic GLs, whereas the depletion of PUFA-containing TAGs in the liver was not mirrored in circulation. Although plasma polar metabolites showed changes in the context of steatosis, potential circulating markers emerged for liver fibrosis with mild statistical significance. With fibrosis progression, there was a trend toward increased levels of tyrosine, quinolinic acid, lactic acid, and kynurenic acid in plasma (p &lt; 0.05, q &gt; 0.05) (Table S3), consistent with their reported roles as key hepatic metabolites implicated in MASLD progression and as proposed circulating biomarkers for MASLD severity or biopsy-proven MASH <sup><xref ref-type="bibr" rid="c32">32</xref>–<xref ref-type="bibr" rid="c35">35</xref></sup>. Overall, despite elevated TAG levels and potential fibrosis indicators, the circulating metabolome is less indicative of early-stage MASLD-related alterations in individuals with obesity and obesity-related co-morbidities.</p>
</sec>
<sec id="s2c">
<title>Integrative view of liver metabolism remodeling</title>
<p>We next integrated the hepatic metabolome and transcriptome to characterize metabolic remodeling in obese individuals during early disease development.</p>
<sec id="s2c1">
<title>Lipid metabolism</title>
<p>In the liver, accumulation of GLs and mild reduction of GPLs were the main features of the metabolome changes (see <xref rid="fig2" ref-type="fig">Figure 2</xref>). Consistent with this observation, we identified genes implicated in the homeostasis of GLs and GPLs (<xref rid="fig3" ref-type="fig">Figure 3A</xref> and Figure S3). Genes such as <italic>DGAT2</italic>, <italic>PNPLA3</italic>, and <italic>PLIN3</italic> play a role in LD formation and TAG and DAG metabolism <sup><xref ref-type="bibr" rid="c36">36</xref></sup>. GPL metabolism was also markedly altered, including key genes such as <italic>LPCAT1</italic>, <italic>PLD2</italic>, <italic>PCYT2</italic>, <italic>ETNK</italic>2 and that are implicated in a compensatory response to the shift in phospholipid metabolism and the increased turnover of GPLs <sup><xref ref-type="bibr" rid="c37">37</xref>, <xref ref-type="bibr" rid="c38">38</xref></sup>. In individuals with advanced hepatic fibrosis, expression levels of the genes involved in primary bile acid biosynthesis, such as <italic>SLC27A5, AMACR</italic>, <italic>ACOX2</italic>, <italic>AKR1C4</italic>, and <italic>BAAT</italic>, were lower. In addition, a group of cytochrome P450 (CYP) genes were downregulated during the progression of fibrosis, particularly those involved in CYP-dependent PUFA metabolism (i.e., linoleic acids and arachidonic acids into bioactive molecules) and steroid hormone biosynthesis <sup><xref ref-type="bibr" rid="c39">39</xref>, <xref ref-type="bibr" rid="c40">40</xref></sup> (<xref rid="fig3" ref-type="fig">Figure 3A</xref>). Overall, our data highlights a number of genes encoding the enzyme subunits of anabolic and catabolic lipid metabolism in early MASLD, and some of these gene signals were consistently observed in both the EU and VA cohorts <sup><xref ref-type="bibr" rid="c26">26</xref>, <xref ref-type="bibr" rid="c27">27</xref></sup>.</p>
<fig id="fig3" position="float" orientation="portrait" fig-type="figure">
<label>Figure 3:</label>
<caption><title>Integrative view of key metabolic pathways implicated in liver metabolism in obese individuals with MASLD.</title><p>(A) Heatmap of log2 fold changes from pair-wise analysis of lipid metabolism-related genes. Association with steatosis (S) and fibrosis (F) is indicated by black dots (q value &lt; 0.05, top). Results were cross-referenced with two published cohorts (VA cohort, GSE130970; EU cohort, GSE135251, bottom). Asterisks indicate genes with a q-value &lt; 0.05 and a consistent change in direction within our cohort. (B) KEGG metabolic pathways with at least 4 genes or metabolites significantly associated with steatosis [S] or fibrosis [F]. (C) Integrative map of gene and metabolite alterations associated with steatosis (left half of each box/circle) and fibrosis (right half of each box/circle). (D) Metabolite alterations corresponding to the advancement of steatosis grades (x-axis).</p></caption>
<graphic xlink:href="632747v2_fig3.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="s2c2">
<title>Dysregulated metabolic pathways during steatosis progression</title>
<p>To explore the variation in metabolic activities using dual-omic descriptors, we prioritized key pathways with both dysregulated metabolites and gene expressions (<xref rid="fig3" ref-type="fig">Figure 3B</xref>). In addition to significant GL and GPL remodeling, we also identified altered pathways of amino acid metabolism at both omics levels. Elevated levels of amino acids including glycine, glutamic acid, arginine, serine, and alanine in steatotic livers may reflect increased collagen synthesis and ECM remodeling during MASLD progression <sup><xref ref-type="bibr" rid="c41">41</xref>, <xref ref-type="bibr" rid="c42">42</xref></sup> (<xref rid="fig3" ref-type="fig">Figure 3C-D</xref>). Notably, aromatic amino acids including phenylalanine, tyrosine, and tryptophan were lower in subjects with advanced steatosis (<xref rid="fig3" ref-type="fig">Figure 3D</xref>). Dual-omics data revealed consistent downregulation of tryptophan metabolism, encompassing both the indole and melatonin pathways (<xref rid="fig3" ref-type="fig">Figure 3C</xref>). However, quinolinic acid, a key metabolite in the kynurenine pathway and a product of tryptophan catabolism, was significantly elevated in association with both hepatic steatosis and fibrosis. Collectively, early MASLD development is associated with reduced aromatic amino acid levels and the altered tryptophan catabolic flux in the liver, potentially reflecting the aberrant gut–liver axis communication in obese MASLD patients <sup><xref ref-type="bibr" rid="c43">43</xref>–<xref ref-type="bibr" rid="c45">45</xref></sup>.</p>
<p>Moreover, homocysteine and its upstream metabolite S-adenosylhomocysteine levels were significantly higher in steatotic livers, indicating dysregulated methylation with excessive lipid storage <sup><xref ref-type="bibr" rid="c46">46</xref></sup>. However, the accumulation these metabolites was mitigated by fibrosis-associated downregulation in key enzymes including <italic>GNMT</italic>, <italic>MAT1A</italic>, and <italic>AHCY</italic> (<xref rid="fig3" ref-type="fig">Figure 3C</xref>), which have been linked to liver pathogenesis in in vivo models <sup><xref ref-type="bibr" rid="c47">47</xref>–<xref ref-type="bibr" rid="c50">50</xref></sup>. These suggest that an imbalance in methylation reactions of DNA and proteins may be an important mediator of liver fibrogenesis in obese individuals.</p>
<p>In addition, we observed elevated levels of the antioxidant coenzyme Q10 (CoQ10; ubiquinone) and its intermediates CoQ6 and CoQ9 in the steatotic liver (<xref rid="fig3" ref-type="fig">Figure 3D</xref>). Higher levels of two other antioxidants, taurine and alpha-tocopherol (vitamin E), were also detected. Another indicator of oxidative stress, hydroxybutyric acid, was increased in advanced steatosis and is also recognized as an early marker of insulin resistance <sup><xref ref-type="bibr" rid="c51">51</xref></sup>. Overall, the progression of liver steatosis is accompanied by extensive changes in amino acid metabolism and oxidative stress regulation.</p>
</sec>
<sec id="s2c3">
<title>Dysregulated genes involved in mitochondrial function and autophagy</title>
<p>In the liver metabolome, lower levels of hepatic long-chain acyl-carnitine (CAR) species were observed with advanced steatosis (CAR 18:2 and 20:4, Table S4), suggesting dysregulated fatty acid transmembrane transport and β-oxidation <sup><xref ref-type="bibr" rid="c52">52</xref>, <xref ref-type="bibr" rid="c53">53</xref></sup>. To systematically assess mitochondrial functions beyond β-oxidation, we mapped steatosis and fibrosis-associated genes to MitoCarta3.0 <sup><xref ref-type="bibr" rid="c54">54</xref></sup>. Distinct mitochondrial dysfunction patterns emerged: steatosis involved 26 downregulated and 55 upregulated mitochondrial-function genes, including 16 related to mtDNA maintenance, while fibrosis was linked to 151 downregulated (dark green) and only 15 upregulated (orange) genes (<xref rid="fig4" ref-type="fig">Figure 4A</xref> and Table S6). These transcriptional shifts suggest that hepatic fibrosis involves broad mitochondrial impairment, contributing to oxidative stress and reduced ATP production, which could favor the exacerbation of steatohepatitis <sup><xref ref-type="bibr" rid="c15">15</xref></sup>.</p>
<fig id="fig4" position="float" orientation="portrait" fig-type="figure">
<label>Figure 4:</label>
<caption><title>Dysregulated mitochondrial function and autophagy during the progression of steatosis and fibrosis.</title>
<p>Gene expression patterns related to mitochondrial metabolism (A), mitochondria-related biological processes (A), autophagy activation (B), and lysosomal biogenesis (B) with statistical association to steatosis and fibrosis. S, steatosis. F, fibrosis.</p></caption>
<graphic xlink:href="632747v2_fig4.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Autophagy serves as a critical cellular response mechanism to the overload of intrahepatic TAG and cholesterol <sup><xref ref-type="bibr" rid="c55">55</xref>, <xref ref-type="bibr" rid="c56">56</xref></sup>. Metabolomic analysis showed increased free cholesterol and reduced levels of CE 18:1 and 18:2, the predominant hepatic CE species <sup><xref ref-type="bibr" rid="c57">57</xref></sup> (Figure S4A), supporting prior findings that CE de-esterification contributes to elevated free cholesterol in MASLD <sup><xref ref-type="bibr" rid="c58">58</xref></sup>. Although autophagy has been linked to HSC activation <sup><xref ref-type="bibr" rid="c59">59</xref>, <xref ref-type="bibr" rid="c60">60</xref></sup>, its involvement in MASLD progression remains unclear. Using a list of predictive genes in autophagy activation <sup><xref ref-type="bibr" rid="c61">61</xref></sup>, we found that autophagy activation and lysosome biogenesis were more strongly associated with steatosis than fibrosis, with upregulated key autophagy genes such as <italic>ULK1</italic> and <italic>MTOR</italic> (<xref rid="fig4" ref-type="fig">Figure 4B</xref>). Further investigation of over 600 autophagy genes <sup><xref ref-type="bibr" rid="c61">61</xref></sup> (Table S7 and Figure S4B) revealed active autophagy initiation in early MASLD, where 119 genes across pathways including mTORC and upstream effectors, lysosome, and autophagy core assembly genes displayed altered expression levels. This suggests that autophagy serves as an adaptive response to hepatic lipotoxicity during steatosis, but its activation may decline as the disease progresses, as evidenced by the downregulation of key regulators such as <italic>NR1H4</italic>, <italic>SIRT5</italic>, <italic>FOS</italic>, and <italic>EGR1</italic> (Figure S4B), thereby impairing liver metabolism <sup><xref ref-type="bibr" rid="c62">62</xref></sup>.</p>
</sec>
</sec>
<sec id="s2d">
<title>Molecular signatures of hepatic steatosis and fibrosis are mutually independent</title>
<p>To gain insights into the dual-omic data in the liver further, we performed a partial-correlation network analysis to integrate liver transcriptomic, metabolomic, and clinical data <sup><xref ref-type="bibr" rid="c31">31</xref></sup>. The resulting subnetwork highlighted distinct molecular signatures correlated with steatosis and fibrosis (<xref rid="fig5" ref-type="fig">Figure 5A</xref>). Steatosis was primarily associated with hepatic neutral lipid accumulation and related metabolomic alterations, whereas fibrosis was predominantly linked to transcriptional changes, including the upregulation of genes involved in ECM remodeling (e.g., <italic>TGFB3</italic>, <italic>FSTL1</italic>), signal transduction (e.g., <italic>RHOU</italic>, <italic>DOK3</italic>), and metabolism (e.g., <italic>CYP2C19</italic>, <italic>PNPLA4</italic>, <italic>SGPL1</italic>). These findings underscore the presence of distinct molecular pathways driving the progression of steatosis and fibrosis.</p>
<fig id="fig5" position="float" orientation="portrait" fig-type="figure">
<label>Figure 5:</label>
<caption><title>Steatosis and fibrosis as independent processes.</title>
<p>(A) Network of genes, metabolites, and histological features (fibrosis and steatosis) using partial correlation analysis as described in the methods. (B) Venn diagrams depicting the number of genes significantly associated with steatosis and fibrosis (q value &lt; 0.05). (C) Gene ontology (GO) enrichment of gene sets specific to steatosis or fibrosis.</p></caption>
<graphic xlink:href="632747v2_fig5.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>In our transcriptomics analysis, 992 and 1,251 gene markers were identified as significantly associated with the histological features of steatosis and fibrosis, respectively, with limited overlap between the two sets (<xref rid="fig5" ref-type="fig">Figure 5B</xref> and Table S5, q value &lt; 0.05), suggesting unique transcriptomic regulations underlie each feature. Functional enrichment analysis further supported this distinction, revealing largely non-overlapping biological processes associated with each gene set (Figure S5 and Table S8).</p>
<p>To distinguish gene signatures uniquely linked to steatosis or fibrosis, we included the other histological feature as a covariate in the regression model. This allowed us to define steatosis-specific genes (independent of fibrosis) and fibrosis-specific genes (independent of steatosis) (Table S9). Since steatosis precedes fibrosis in the pathophysiology of MASLD, enrichment analysis of steatosis- and fibrosis-specific genes revealed a ‘pseudo-temporal’ progression of biological processes (<xref rid="fig5" ref-type="fig">Figure 5C</xref>). More pathways were found to be associated with fibrosis than with steatosis. Steatosis-specific upregulated genes were enriched in protein glycosylation, inflammatory response, lipid catabolism, and lysosome organization.</p>
<p>In contrast, fibrosis-specific genes showed downregulation of various metabolic pathways and upregulation of processes related to ECM remodeling, hypoxia, signaling, and cell morphogenesis. Additionally, apoptosis-related pathways were suppressed in steatosis but activated in fibrosis, while nucleotide metabolism showed the opposite trend, suggesting dynamic regulation of cell death and proliferation during MASLD development. These findings implicate distinct and lesion-specific gene regulatory programs in early MASLD progression.</p>
<p>Moreover, consistent with previous observations showing that hepatic fibrosis correlates with insulin resistance parameters in clinical assays (<xref rid="fig1" ref-type="fig">Figure 1C</xref>), we found that individuals with diabetic MASLD exhibited a greater number of downregulated genes as fibrosis progressed than non-diabetic MASLD individuals (Table S10). Since most of the suppressed genes in the diabetic subgroup are involved in metabolism (e.g., <italic>BAAT</italic>, <italic>G6PC1</italic>, <italic>SULT2A1</italic>, <italic>MAT1A</italic>), we hypothesize that diabetes may exacerbate the metabolic dysfunction associated with hepatic fibrosis progression.</p>
</sec>
<sec id="s2e">
<title>Gene signatures of fibrosis initiation</title>
<p>To further explore representative gene signatures in the development of fibrosis, we identified 213 genes as progressive markers by comparisons of gene expression levels against two different baselines (no MASLD and steatosis; details provided in the methods; Table S11). Among them, 75 of these markers overlapped with fibrosis-associated genes in the VA cohort and 35 overlapped with the EU cohort (<xref rid="fig6" ref-type="fig">Figure 6A</xref>) <sup><xref ref-type="bibr" rid="c26">26</xref></sup>, resulting in 130 novel fibrosis markers. Pathway analysis of these fibrosis markers highlighted prominent roles for signal transduction and ECM organization/ disassembly, as expected (Figure S6A). To infer the cell type-of-origin for signals from bulk sequencing, we mapped progressive fibrosis markers onto a human liver single-cell atlas <sup><xref ref-type="bibr" rid="c63">63</xref></sup>. Upregulated genes appeared to reflect changes from different cell types, whereas downregulated markers were predominantly hepatocyte-specific (<xref rid="fig6" ref-type="fig">Figure 6A</xref>, left panel). This suggests that in the early stages of liver fibrosis development, the transcriptional programs are activated in different cell types, while hepatocyte functions potentially become muted during the process. Meanwhile, we observed fibrosis-associated upregulation of genes involved in TGF-β and SMAD signaling cascades (<italic>TGFB1</italic>, <italic>TGFB3</italic>, and <italic>INHBA</italic>), ECM activators <sup><xref ref-type="bibr" rid="c64">64</xref>–<xref ref-type="bibr" rid="c66">66</xref></sup> (<italic>ITGAV</italic>, <italic>LOXL2</italic>, <italic>THBS1</italic>, <italic>MMP9</italic>, and <italic>MMP14</italic>), regulators (<italic>CDK8</italic>, <italic>CTDSP2</italic>, <italic>HDAC1</italic>, and <italic>HDAC7</italic>), and downstream targets (<italic>TIMP1</italic>, <italic>MMP9</italic>, and <italic>COL5A2</italic>) (Figure S6B). This aligns well with previous reports that TGF-β signaling and HSC activation drive fibrosis during MASLD progression <sup><xref ref-type="bibr" rid="c67">67</xref>, <xref ref-type="bibr" rid="c68">68</xref></sup>.</p>
<fig id="fig6" position="float" orientation="portrait" fig-type="figure">
<label>Figure 6:</label>
<caption><title>Liver fibrosis signatures and potential therapeutic targets of fibrosis initiation.</title>
<p>(A) Top 60 fibrosis markers in the liver. A total of 213 genes were identified, from which the top 30 upregulated and top 30 downregulated genes are visualized. The middle plot (blue bar on top) shows the comparison of individuals with fibrosis and without pathology (baseline - “no MASLD”). For the right plot (red bar), individuals with fibrosis were compared to those with steatosis but no fibrosis (baseline – “steatosis but no fibrosis”). Results were cross-referenced with two published cohorts (VA cohort, GSE130970; EU cohort, GSE135251, right). Asterisks indicate genes with a q-value &lt; 0.05 and a consistent change in direction within our cohort. The average gene expressions of liver cell types were obtained from GSE115469 at the log2CPM level (left). Dots in the single cell map indicate zero expression in the corresponding cell types. (B) Enrichment of pathways in the transition from simple steatosis to the onset of fibrosis. (C) Protein-protein interaction network of GTPases and their regulators. Nodes are colored based on gene type, with borders indicating the direction of gene regulation. Node size corresponds to the significance of the genes in relation to fibrosis grades within this cohort. GEFs: Guanine nucleotide exchange factors. GAPs: GTPase-activating proteins. (D) Comparison of expression level changes in GTPase-related genes between this human cohort and an independent 3D spheroid MASH system. Log2 fold change for the human cohort was calculated by comparing patients with grade 2 or 3 fibrosis to those without fibrosis or steatosis. Genes with the same direction of change are colored in red, while others are colored in purple. (E) Expression of GTPase-related genes in patient-derived 3D liver spheroids: control spheroids, spheroids from patients with MASH, and Elafibranor-treated MASH spheroids (n = 4). Sixty-eight genes with a p-value &lt; 0.05 from the ANOVA test were plotted in the diagram, with blue lines highlighting 24 genes that exhibited increased expression in the MASH group compared to the control group.</p></caption>
<graphic xlink:href="632747v2_fig6.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Given that the transition from simple steatosis to the onset of fibrosis marks a critical window for disease management, we compared gene expression profiles between individuals with fibrosis accompanied by steatosis and those with steatosis but without fibrosis (Table S12). Notably, the top-enriched pathways in this comparison emerged as GTPase signaling and its regulation, signal transduction, and innate immune response (<xref rid="fig6" ref-type="fig">Figure 6B</xref>). Moreover, we identified 37 GTPase-related genes displaying significant associations with fibrosis progression (Figure S7A and Table S13). To explore the potential role of GTPase signaling in fibrosis, we examined an inventory of 251 genes encoding GTPases, GTPase-activating proteins (GAPs), and guanine nucleotide exchange factors (GEFs), analyzing their interactome using the Human Cell Map <sup><xref ref-type="bibr" rid="c69">69</xref></sup> and a protein-protein interaction network<sup><xref ref-type="bibr" rid="c70">70</xref>, <xref ref-type="bibr" rid="c71">71</xref></sup>.</p>
<p>Among the 6,971 proteins that have been tested for physical interaction or subcellular proximity with GTPase-related genes, 508 of these associated significantly with fibrosis progression in our cohort (<xref rid="fig6" ref-type="fig">Figure 6C</xref>). The network indicates that GTPases and their regulators interact with a wide range of fibrosis genes, with <italic>ARF3</italic> and <italic>RAC1</italic> being central hubs of the network. Functional enrichment of the core nodes revealed that the GTPase network regulates intracellular transport, actin cytoskeleton organization, exocytosis, and other biological processes during fibrosis progression (Figure S7B). Therefore, GTPases and their regulators are co-regulated with fibrosis-related genes encoding their protein interaction partners, supporting the likelihood of a functional link between GTPases and hepatic fibrosis. This is supported by TGF-β genes positively correlated with co-expressed GTPase-related genes (Figure S7C), suggesting a potential link between TGF-β signaling and GTPase pathways.</p>
<p>To experimentally validate our findings, the altered expression of GTPase-related genes was explored in an independent system using an established model of 3D liver spheroids in which hepatic cells remain viable and functional for multiple weeks <sup><xref ref-type="bibr" rid="c72">72</xref>–<xref ref-type="bibr" rid="c74">74</xref></sup>. Specifically, we co-cultured primary human hepatocytes with Kupffer and stellate cells isolated from patients with histologically confirmed MASH <sup><xref ref-type="bibr" rid="c75">75</xref></sup> and examined the overall expression profile of GTPase-regulated genes between our human cohort and the ex vivo system. The expression of GTPases were largely concordant when assessing human patients and the 3D spheroid system (<xref rid="fig6" ref-type="fig">Figure 6D</xref>). In comparison to the control group, spheroids from MASH patients demonstrated an upregulation of 24 genes encoding GTPases and their regulators (<xref rid="fig6" ref-type="fig">Figure 6E</xref>). Remarkably, the treatment of liver spheroids with elafibranor, a dual PPARα/δ agonist <sup><xref ref-type="bibr" rid="c76">76</xref></sup>, restored the expression levels of 17 (70%) GTPase-related genes back to the baseline (<xref rid="fig6" ref-type="fig">Figure 6E</xref>). This independent system further suggests that GTPases may play a role in MASLD pathogenesis and the fibrotic response.</p>
<p>Since HSCs are the main liver cell type responsible for activating fibrosis, we next assessed whether inhibition of GTPase activity in an immortalized HSC cell line, the LX-2 cells, could attenuate markers of fibrogenesis (Figure S8A). Selective GTPase inhibitors targeting Rac1 (NSC23766) and Cdc42 (ML141) reduced the mRNA expression of <italic>COL1A1</italic> and <italic>COL1A2</italic>, as well as pro-collagen secretion (Figure S8) under basal conditions. TGF-β1 mediated activation induced the expected increase in collagen secretion and gene expression which was attenuated by Rac1 inhibitor (NSC23766) and to a lesser extent by ML141. In addition, examination of previously published transcriptomic data of HSCs isolated from CCL<sub>4</sub>-mediated liver fibrosis in mice <sup><xref ref-type="bibr" rid="c77">77</xref></sup>, revealed the upregulation of GTPases comparable to the steatosis-to-fibrosis transition in our human cohort, with a temporal pattern aligning with hepatic collagen deposition (Figure S9A). Further, in a human liver organoid model, TGF-β induced increased expression of GTPase-related genes in hepatocytes and HSCs, but not in fibroblasts <sup><xref ref-type="bibr" rid="c78">78</xref></sup> (Figure S9B), suggesting a potential feedforward loop involving the TGF-β/GTPase axis between hepatocytes and HSCs. To investigate intercellular crosstalk in GTPase regulation, we examined key GTPase-related genes in LX-2 cells, hepatocyte monocultures, and spheroid co-cultures (including hepatocytes, HSCs, Kupffer cells). As shown in Figure S10, TGF-β1 induced a potential increase in <italic>VAV1</italic> and <italic>DOCK2</italic> consistent in co-cultures, hepatocytes, and LX-2 cells, while <italic>RAC1</italic>, <italic>RAB32</italic>, and <italic>RHOU</italic> showed cell type-specific responses. These findings indicate that multiple hepatic cell types mediate GTPase regulation, underscoring intercellular crosstalk.</p>
<p>Overall, these additional experiments and analyses of datasets identified upregulated GTPase-related genes during fibrosis initiation (Figure S9C). However, further in-depth mechanistic studies are needed to validate this association.</p>
</sec>
</sec>
<sec id="s3">
<title>Discussion</title>
<p>In this study, we performed a comprehensive omics-based analysis of a cohort of 109 obese individuals with early MASLD. Through integrative dual-omics approaches, we mapped the liver and plasma metabolomes and identified distinct hepatic molecular features associated with steatosis and fibrosis progression. Notably, fibrosis was closely connected to global reprogramming of hepatic gene expression, with GTPase-related genes emerging as possible mediators of fibrosis initiation.</p>
<p>In this obesity cohort, the plasma metabolome showed limited alterations in MASLD, with the exception of elevated circulating TAGs. This contradicts with McGlinchey <italic>et al</italic>., who reported more than 20 differential metabolites in the serum metabolome <sup><xref ref-type="bibr" rid="c19">19</xref></sup>. Our conjecture is that the discrepancy stems from the different disease spectrum covered in the two studies, as the cohort in the other study included advanced MASLD cases with NAS score ≥ 4 (63.4%). In addition, our study focused exclusively on obese individuals (median BMI &gt; 43.0), substantially higher than the other study. A recent report has highlighted distinct metabolite signatures between obese and lean individuals with MASLD, noting fewer differential metabolites in obese individuals than lean ones <sup><xref ref-type="bibr" rid="c79">79</xref></sup>. This suggests that plasma lipidome is less reflective of liver pathology in patients with obesity compared to lean individuals. Similarly, a BMI-stratified multivariable model revealed distinct circulating MASLD metabolite signatures across different degrees of obesity, with lean subgroups showing significantly altered circulating lipotoxic intermediates <sup><xref ref-type="bibr" rid="c80">80</xref></sup>. Therefore, as shown in <xref rid="fig2" ref-type="fig">Figure 2C</xref>, we hypothesize that co-occurring morbidities in obesity may obscure liver-derived metabolic signals in the plasma, particularly in early-stage MASLD. Given that obese individuals represent the predominant population affected by MASLD, it is reasonable to conclude that whether blood analysis of metabolites attains diagnostic accuracy in identifying disease progression at early stages depends on the disease spectrum covered in a study and remains context-specific. However, the emergence of liquid biopsies, fine needle liver biopsies, and the evaluation of liver-specific extracellular vesicles may open up other minimally invasive diagnostic opportunities <sup><xref ref-type="bibr" rid="c81">81</xref></sup>.</p>
<p>The strength of our study is the characterization of hepatic pathophysiology in relation to steatosis and fibrosis via transcriptome and metabolome-wide variations. Consistent with general expectation, our work highlighted altered hepatic lipid metabolism in human liver tissues of obese patients at both metabolite and gene levels <sup><xref ref-type="bibr" rid="c82">82</xref>–<xref ref-type="bibr" rid="c84">84</xref></sup>. Consistent with the variations in GLs, higher expression levels of <italic>DGAT2</italic>, <italic>PNPLA3</italic>, and <italic>PLIN3</italic> were associated with steatosis progression. The higher expression of <italic>DGAT2</italic>, which encodes a key enzyme catalyzing the last step of de novo TAG synthesis, implies enhanced integration of TAGs into LDs in the endoplasmic reticulum, which presumably alleviates lipid-induced ER stress and evades accumulation of lipotoxic lipids <sup><xref ref-type="bibr" rid="c85">85</xref></sup>. Upregulation of <italic>PLIN3</italic> was correlated with higher grades of both fibrosis and steatosis. The protein encoded by <italic>PLIN3</italic>, along with other PLIN proteins <sup><xref ref-type="bibr" rid="c86">86</xref></sup>, plays an important role in LD stabilization and the prevention of TAG hydrolysis, thus potentially contributing to hepatic steatosis <sup><xref ref-type="bibr" rid="c87">87</xref></sup>. In addition, although previous animal studies have reported increased levels of sphingolipids in MASLD models <sup><xref ref-type="bibr" rid="c19">19</xref>, <xref ref-type="bibr" rid="c88">88</xref></sup>, we did not observe this in patients with obesity at early stages of the disease. Sphingolipid alterations varied across cohorts with differing patient compositions <sup><xref ref-type="bibr" rid="c18">18</xref>, <xref ref-type="bibr" rid="c19">19</xref>, <xref ref-type="bibr" rid="c89">89</xref></sup>, suggesting that sphingolipid metabolism may be dependent on disease stage, obesity status, and exhibit discrepancies between humans and mice.</p>
<p>Beyond lipid metabolism, other metabolic pathways and processes also exhibited dysregulation at the dual-omics level. Specifically, with excessive lipid deposition, we observed higher levels of taurine and vitamin E, both of which have antioxidant effects and likely reflect the hepatic response to oxidative stress <sup><xref ref-type="bibr" rid="c90">90</xref>–<xref ref-type="bibr" rid="c92">92</xref></sup>. Importantly, amino acid metabolism was markedly dysregulated as steatosis progressed, characterized by elevated hepatic levels of serine, arginine, glutamic acid, glycine, and alanine, along with decreased levels of the aromatic amino acids phenylalanine, tryptophan, and tyrosine. A previous <italic>in vitro</italic> study also demonstrated that palmitic acid supplementation disrupted the metabolism of the aromatic amino acids in PH5CH8 and HepG2 cells <sup><xref ref-type="bibr" rid="c93">93</xref></sup>. As microbiota-derived metabolites, dysregulation in these amino acid may reflect disrupted gut function and may affect the de novo synthesis of nicotinamide adenine dinucleotide in MASLD patients <sup><xref ref-type="bibr" rid="c94">94</xref></sup>. Moreover, we also observed evidence of autophagy activation concurrent with intrahepatic lipid and cholesterol accumulation, wherein lysosome-associated genes were uniquely associated with steatosis, as shown in <xref rid="fig4" ref-type="fig">Figure 4B</xref> and highlighted in <xref rid="fig5" ref-type="fig">Figure 5C</xref> by the enrichment of lysosome organization among steatosis-specific processes. This autophagic response most likely represents a protective mechanism to ameliorate steatosis <sup><xref ref-type="bibr" rid="c95">95</xref></sup>; however, the downregulation of autophagy regulators during fibrosis development may exacerbate liver metabolic dysfunction.</p>
<p>As liver fibrosis progressed, the expression levels of genes involved in primary bile acid biosynthesis, PUFA metabolism, and steroid hormone biosynthesis were lower, especially <italic>ACADS</italic>, <italic>ACADSB</italic>, and <italic>ACADM</italic> which encode key enzymes in the initial stage of catalyzing fatty acid β-oxidation, and <italic>HADH</italic> and <italic>ACAA1</italic>, which encode enzymes that act in the late stage of β-oxidation <sup><xref ref-type="bibr" rid="c96">96</xref></sup>. Moreover, mitochondrial-related genes were downregulated with fibrosis progression, particularly those related to the electron transport chain of the mitochondrial inner membrane. This may indicate that pathological oxidative stress and impaired ATP production caused by early mitochondrial dysfunction may aggravate fatty liver inflammation <sup><xref ref-type="bibr" rid="c14">14</xref></sup>, and the augmentation of the inflammatory response may become an important cause of liver fibrosis.</p>
<p>Through univariate hypothesis testing and partial correlation analysis, we revealed distinct molecular signatures correlated with fibrosis and steatosis. Liver fibrosis was associated with gene expression alteration, from which we identified over 200 progressive markers tracking its gradual advancement. Furthermore, GTPase-related genes were dysregulated at the mRNA level with the emergence and progression of fibrosis. Increased expression of GTPase regulators was independently confirmed in 3D primary human liver spheroids, with elafibranor restoring their expression to baseline levels (<xref rid="fig6" ref-type="fig">Figure 6E</xref>). The downregulated expression of GTPase regulators following elafibranor treatment suggests a potential anti-fibrotic mechanism involving GTPase signaling.</p>
<p>GTPase proteins are categorized into several subfamilies such as Rho-, Ras-, and Arf-GTPase based on their sequence and structure <sup><xref ref-type="bibr" rid="c97">97</xref></sup>. GAPs and GEFs are the key regulators of GTPase activity that modulate intrinsic GTPase functions and the GTP-bound state <sup><xref ref-type="bibr" rid="c98">98</xref></sup>. Only a few studies have elucidated the role of GTPases in liver pathology <sup><xref ref-type="bibr" rid="c99">99</xref>–<xref ref-type="bibr" rid="c102">102</xref></sup>. For instance, <italic>Rap1a</italic> was identified as a signaling molecule that suppresses both gluconeogenesis and hepatic steatosis <sup><xref ref-type="bibr" rid="c102">102</xref></sup>. The Rab23-specific GAP, <italic>GP73</italic>, has been implicated in triggering non-obese MASLD <sup><xref ref-type="bibr" rid="c101">101</xref></sup>. Additionally, Rho-GTPase signaling through the ROCK1/AMPK axis regulates de novo lipogenesis during overnutrition <sup><xref ref-type="bibr" rid="c99">99</xref></sup>, while an immune-related GTPase triggers lipophagy and prevents hepatic lipid storage <sup><xref ref-type="bibr" rid="c100">100</xref></sup>. However, evidence regarding the role of GTPase regulation in human liver is limited, particularly in the context of liver fibrosis initiation and progression, and a thorough mechanistic investigation is warranted to establish causality.</p>
<p>In recent years, dual- and multi-omics strategies have gradually emerged in MASLD research. A proteo-transcriptomic map constructed from the EU cohort’s liver RNA sequencing data and circulating proteome identified four promising protein biomarkers <sup><xref ref-type="bibr" rid="c28">28</xref></sup>. Among these, <italic>AKR1B10</italic> was also identified in our study as a key gene related to lipid metabolism, showing strong associations with both steatosis and fibrosis (<xref rid="fig3" ref-type="fig">Figure 3A</xref>), which highlights its potential as a biomarker even in the early stages of MASLD. Additionally, we observed mitochondrial dysregulation linked to the progression of liver fibrosis (<xref rid="fig4" ref-type="fig">Figure 4A</xref>). Consistent with our findings, a multi-omics study in obese individuals with MASLD also revealed mitochondrial dysfunction at the hepatic protein level. The study further emphasized similar mitochondrial disruptions in adipose tissue, suggesting the liver-adipose tissue interaction in obesity-related MASLD <sup><xref ref-type="bibr" rid="c103">103</xref></sup>. Beyond inter-tissue interactions, Raverdy <italic>et al</italic>. reported the heterogeneity of MASLD molecular signatures in relation to varying degrees of cardiovascular risk and type 2 diabetes <sup><xref ref-type="bibr" rid="c104">104</xref></sup>. This further highlights the impact of systemic metabolic conditions on MASLD progression. In our analysis of diabetic individuals, we identified more downregulated metabolic genes associated with fibrosis, supporting the notion that insulin resistance may exacerbate metabolic dysregulation and interferes with the disease trajectory.</p>
<p>Overall, our integrative investigation offers one of the most detailed molecular landscapes of early stage MASLD in individuals with obesity, with comprehensive descriptors of the early remodeling of hepatic metabolism associated with initiation of fibrosis in the steatotic liver.</p>
<sec id="s3a">
<title>Limitations of the study</title>
<p>This study focused on 109 patients with early-stage MASLD, potentially overlooking molecular changes associated with later disease stages. To address this, we cross-referenced our findings with two external cohorts (EU and VA). Additionally, we identified GTPase-related genes as potential future targets for reversing liver fibrosis. While preliminary validation has been conducted in different systems, further investigation is required to confirm the causal role of specific GTPases in fibrosis initiation especially in HSCs and to elucidate how GTPase signaling contributes to collagen production throughout the progression of MASLD.</p>
</sec>
</sec>
<sec id="s4">
<title>Materials and Methods</title>
<sec id="s4a" sec-type="ethics-statement">
<title>Ethics statement</title>
<p>Participants provided written and verbal informed consent. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the University of Melbourne Human Ethics Committee (ethics ID 1851533), The Avenue Hospital Human Research Ethics Committee (Ramsay Health; ethics ID WD00006, HREC reference number 249), the Alfred Hospital Human Research Ethics Committee (ethics ID GO00005), and Cabrini Hospital Human Research Ethics Committees (ethics ID 09-31-08-15). All work on the data from human samples in Sweden was approved by Etikprövningsmyndigheten (Dnr 2024-07917-01).</p>
</sec>
<sec id="s4b">
<title>Cohort recruitment</title>
<p>A detailed medical history was taken, and metabolic comorbidities were noted including the presence of previously diagnosed hypertension and diabetes assessed by oral glucose tolerance testing. Exclusion criteria included: age &lt;18 years, previous gender reassignment, other causes of chronic liver disease and/or hepatic steatosis including Wilson’s disease, α-1-antitrypsin deficiency, viral hepatitis, human immunodeficiency virus, primary biliary cholangitis, autoimmune hepatitis, genetic iron overload, hypo- or hyperthyroidism, coeliac disease, as well as recent (within three months of screening visit) or concomitant use of agents known to cause hepatic steatosis including corticosteroids, amiodarone, methotrexate, tamoxifen, valproic acid and/or high dose oestrogens <sup><xref ref-type="bibr" rid="c105">105</xref></sup>. Further exclusion criteria included potential for alcohol-induced liver disease, which was assessed through a modified version of the alcohol use disorders identification test (AUDIT) <sup><xref ref-type="bibr" rid="c105">105</xref>, <xref ref-type="bibr" rid="c106">106</xref></sup>. Following histological assessment, patients with liver slice weighing less than 2mg were excluded from the omics analysis.</p>
<p>Eligible patients with obesity scheduled for primary or secondary sleeve gastrectomy, gastric bypass, or the insertion of a laparoscopic-adjustable band were prospectively enrolled. All patients were fasted for 8-12 h overnight and venous blood was taken before the induction of anaesthesia. Blood was transferred to 2 x K2E Ethylenediaminetetraacetic acid (EDTA), 2 x SST™ II Advance and 1 x FX 5 mg bio-containers for subsequent storage or clinical/biochemical assessments. All blood samples were sent to Melbourne PathologyTM (Victoria, Australia) for standardised measurement of biochemical and metabolic variables, except for one bio-container of EDTA. Standard blood analyses were performed for electrolytes, full blood examination, glucose, glycosylated haemoglobin, insulin, C-peptide, cholesterol, triglycerides, and liver function assessed by ALT, AST, GGT, and alkaline phosphatase (ALP), and screening blood tests for liver disease. The remaining blood within the EDTA tube was spun at 8000 x g for 10 min and the plasma was collected and stored at -80°C for mass spectrometry analyses.</p>
</sec>
<sec id="s4c">
<title>Liver biopsy collection and histological feature assessment</title>
<p>An ∼ 1 cm<sup>3</sup> wedge liver biopsy was collected from the left lobe of the liver during surgery. The liver was cut into two portions. One portion was placed in formalin and transported to TissuPath<sup>TM</sup> (Mount Waverley, Victoria), paraffin embedded and processed for histological analysis. Samples were graded according to the Clinical Research Network NAFLD activity score (NAS) <sup><xref ref-type="bibr" rid="c107">107</xref></sup> and Kleiner classification of liver fibrosis <sup><xref ref-type="bibr" rid="c108">108</xref></sup> by a liver pathologist at TissuPath. Patients with no MASLD were defined by steatosis score of 0, regardless of inflammation or fibrosis grade 1. MASL patients were defined by a steatosis score ≥1 with or without lobular inflammation. MASH was defined by the joint presence of steatosis, lobular inflammation, and ballooning<sup><xref ref-type="bibr" rid="c108">108</xref></sup>. The remaining portion of liver slices was used for bulk RNA sequencing and untargeted metabolomics analysis.</p>
</sec>
<sec id="s4d">
<title>Sample preparation for untargeted metabolomics</title>
<p>For liver tissue biopsies, each sample containing 50 ± 5 mg of tissue was extracted in 0.8 mL 50:50 (v/v) methanol:chloroform <sup><xref ref-type="bibr" rid="c109">109</xref>, <xref ref-type="bibr" rid="c110">110</xref></sup>. Samples were homogenized for 10 min at 25 Hz with a single 3-mm tungsten carbide bead per tube. Separation of phases was achieved by the addition of 0.4 mL of water followed by vortex-mixing and centrifugation (2400 g, 15 min, 4 °C). After separation, the upper phase (the metabolite-containing fraction) and the lower phase (the lipid-containing fraction) were transferred into separate tubes and dried using SpeedVac.</p>
<p>For plasma samples, 225 µL of methanol was added to 50 µl plasma, and the mixture was vortexed for 10 sec <sup><xref ref-type="bibr" rid="c111">111</xref></sup>. Subsequently, 450 µL chloroform was added and the mixture was incubated for 1h in a shaker. To induce phase separation, 187.5 µL water was added and the mixture was centrifuged at 12,000 rcf for 15 min at 4 °C. The upper phase (the metabolite-containing fraction) phase and lower (the lipid-containing fraction) were collected into separate fresh tubes and dried using SpeedVac.</p>
<p>Dry extracts from the organic fraction were resuspended in the mixed solvent of 90:10 isopropanol: acetonitrile. For the aqueous fraction, 90% acetonitrile was used to reconstitute dry extracts. Plasma samples were reconstituted in 1:4 dilution (plasma-to-solvent: 50 μL/200 μL), and the reconstitution volumes for liver biopsy samples were corrected by the weights of liver slices (tissue-to-solvent: 50 mg/1000 μL). After reconstitution, samples were sonicated for 15 min and centrifuged at 12,000 g for 10 min at 4 °C.</p>
</sec>
<sec id="s4e">
<title>Metabolomics data acquisition and processing</title>
<p>A 1 µL aliquot of the extract was subjected to LC-MS analysis using the Sciex TripleTOF 6600 system coupled with the Agilent 1290 HPLC. For polar metabolite analysis, mobile phase A was water with 10 mM ammonium formate and mobile phase B was acetonitrile with 0.1% formic acid. Flow rate was 0.250 ml/min. The LC gradient started at 3% A, increased to 30% A from 1 to 12 min, then to 90% A from 12 to 15 min, remained at 90% until 18.5 min, and returned to 3%, holding until the end of the 24-min run. For lipid analysis, mobile phase A was prepared by 60:40 water: acetonitrile with 10 mM ammonium formate, and mobile phase B was made by 90:10 isopropanol: acetonitrile with 10 mM ammonium formate. Flow rate was 0.250 ml/min and the total run time is 15.80 min. The LC gradient started at 80% A, decreased to 40% A at 2 min, further decreased to 0% from 2 to 12 min, remained at 0% A until 14 min, then returned to 80% A at 14.10 min, and held at 80% A until the end of run. Mass spectrometry settings were as follows: gas1 50 V, gas2 60V, curtain gas 25V, source temperature 500 °C, IonSpray voltage 5500 V. The collision energy was set to 30 V and 45 V for polar metabolites and lipids, respectively. Fifteen precursors were selected for MSMS fragmentation in the DDA acquisition. The mass range for the RP method was 300 – 1000 m/z and for the HILIC method was 50 – 1000 m/z. In the SWATH acquisition, fixed windows were applied with window widths of 21 Da for the HILIC method and 10 Da for the RP method.</p>
<p>Each tissue type (i.e., plasma and liver) was analyzed as a separate batch. Following sample reconstitution, the supernatants were collected into MS vials and pooled as quality control (QC) samples for each tissue type. For each analytical batch, patient samples were injected in a randomized sequence, along with one QC injection approximately every 10 samples for monitoring instrument stability and calculating the coefficient of variation (CoV). Both reverse phase (RP) and hydrophilic interaction liquid chromatography (HILIC) columns were used for chromatographic separations of organic and aqueous fractions, respectively. For the analysis of aqueous fraction, metabolites were separated on SeQuant ZIC-cHILIC (3 μm, 100Å, 100x2.1 PEEK) column with a flow rate of 0.25 mL/min in a 24-minute run. For the organic fraction, metabolites were separated on RRHD Eclipse Plus C18 (2.1 x 50 mm, 1.8 μm).</p>
<p>Data acquisition was performed in both positive and negative ionization modes. Data-dependent acquisition (DDA) was performed on pooled QC samples for compound identification and SWATH-MS analysis was applied to individual samples for relative quantification. The mass range for the RP method was 300 – 1000 m/z and for the HILIC method was 50 – 1000 m/z. Data was converted into mzML format and was then processed by MetaboKit <sup><xref ref-type="bibr" rid="c112">112</xref></sup> (<ext-link ext-link-type="uri" xlink:href="https://github.com/MetaboKit">https://github.com/MetaboKit</ext-link>). To gain broad metabolite coverage, we curated a data processing pipeline for metabolites identified via spectral matches (MSMS-level, with 915 identifications postprocessing) and those identified solely through mass matches (MS1-level, with 548 identifications postprocessing). For metabolite quantification, the project-specific spectral library generated from DDA analysis was used to extract MS1 and MS2 features from the SWATH data using the MetaboKit DIA module. Compound transitions with a CoV &gt; 30% were excluded from the analysis. For each compound, the precursor or fragment ion with the lowest CoV was selected as the quantifier. For a compound identified in both positive and negative modes using the same column, the peak feature with the lower CoV were selected. Overlapping metabolites in the RP and HILIC datasets are mainly semi-polar lipids, as RP detects compounds with m/z &gt; 300. For lipids identified by both methods, the ones measured on the RP column was selected.</p>
</sec>
<sec id="s4f">
<title>RNA sequencing</title>
<p>Transcriptome sequencing service was provided by Biomarker Technologies (BMK), GmbH. Briefly, RNA were extracted from liver biopsies using Trizol reagent. The quality and quantity of extracted RNA was assessed by Nanodrop (quantity and purity) and Labchip GX (Quality). The cDNA libraries were prepared using Hieff NGS Ultima Dual-mode mRNA Library Prep Kit from Illumina (Yeasen) as per manufacturer’s instructions. RNA sequencing was performed on NoveSeq6000 platform (PE 150 mode). For raw data processing, FastQC (v0.11.9) was used as a quality control check for raw sequencing. Alignment to the reference genome (GRCh38, Ensembl release 77) was performed using STAR (v2.7.9a), and gene expression levels (transcripts-per-million, TPM) were estimated using RSEM (v1.3.1). Gene expression data underwent a logarithmic transformation to log2(TPM + 1) and mean-centering normalization for downstream analyses.</p>
</sec>
<sec id="s4g">
<title>Statistical analysis</title>
<p>All analyses in this study were conducted using R version 4.3.1. Linear regression model was used to evaluate the linear association between histological grades and molecular abundance levels with adjustment for age, sex, BMI, and diabetes. Statistically significantly changed metabolites or genes were defined by controlling the overall type I error at 5% or 10% (q value &lt; 0.05 or 0.1). Spearman rank correlation was used to assess the relationship between the same metabolite in the liver and plasma. This accounts for matrix effects across different tissue types in untargeted analysis by comparing the relative intensity ranking of a metabolite across all samples within each tissue type. Gene overrepresentation analyses were performed using gene ontology recourse by in-house software <sup><xref ref-type="bibr" rid="c113">113</xref></sup>. ClueGO, a plugin app in Cytoscape, was used to visualize enrichment maps <sup><xref ref-type="bibr" rid="c114">114</xref></sup>. Partial correlation network analysis was employed to integrate the two omics layers using an in-house partial correlation network algorithm ACCORD <sup><xref ref-type="bibr" rid="c31">31</xref></sup>. KEGG pathway database was used for the analysis of lipid metabolism and pathway mapping <sup><xref ref-type="bibr" rid="c115">115</xref></sup>. All network visualizations in this study were done using Cytoscape <sup><xref ref-type="bibr" rid="c116">116</xref></sup>.</p>
<p>To investigate MASLD subgroup signatures related to diabetic status, we analyzed linear associations between gene signatures and histological features separately in non-diabetic (n = 71) and diabetic individuals (n = 23). Statistical power was estimated by comparing variance explained in full (y ∼ x + a + b + c) versus reduced (y ∼ a + b + c) regression models, converting the incremental <italic>R<sup>2</sup></italic> into Cohen’s <italic>f<sup>2</sup></italic>, and applying pwr.f2.test at α = 0.05. We further compared gene expression profiles between diabetic (n = 21) and non-diabetic (n = 43) MASLD patients, identifying 166 differentially expressed genes (p &lt; 0.05, |log₂FC| &gt; 0.32). Of these, 54 genes (Table S10) were both differentially expressed and significantly associated with fibrosis progression, and thus marked as signatures in diabetic MASLD.</p>
<p>To identify progressive markers of liver fibrosis, we performed pairwise analyses for fibrosis stages using two distinct baselines: patients with no MASLD and those with steatosis but no fibrosis. 213 markers were characterized as progressive based on the following criteria: a) significant linear association with fibrosis grades, and b) significant differential expression (p value &lt; 0.05 in t-test) in at least two fibrosis stages (e.g., F1 and F2, F2 and F3) compared to both baselines.</p>
<p>To identify independent gene signatures associated specifically with steatosis and fibrosis progression, we applied linear regression models for each outcome adjusting for the other. Steatosis-specific signatures were defined as genes significantly associated with steatosis but not with fibrosis, and vice versa. Metascape was used for meta-analysis of enrichment pathways <sup><xref ref-type="bibr" rid="c117">117</xref></sup>. Pathways with at least 10 hits and p value &lt; 0.05 were considered steatosis- or fibrosis-specific.</p>
<p>For meta-analysis of reference human cohorts, the two RNA-seq datasets of the liver transcriptome, the VA cohort (GSE130970) and the EU cohort (GSE135251), were downloaded from Gene Expression Omnibus, and associations between gene expression (log2 TPM) and fibrosis grades or NAS were analyzed using linear regression. In the EU cohort, the patients without MASH diagnosis were removed from the meta-analysis for the purpose of identifying fibrosis signatures in MASH patients. Human liver single cell dataset was obtained from GSE115469 <sup><xref ref-type="bibr" rid="c63">63</xref></sup>. The mean log2 TPM was calculated for each cell type, and cell specificity was determined by subtracting the mean expression levels across all cell types.</p>
</sec>
<sec id="s4h">
<title>Cross-referencing datasets of mouse models and human liver organoids</title>
<p>The RNA sequencing data (raw counts) for HSCs isolated from liver fibrosis mouse models <sup><xref ref-type="bibr" rid="c77">77</xref></sup> was downloaded from GSE176042 and analyzed using the DESeq2 R package. This previously published study investigated HSC initiation and perpetuation using acute and chronic models, respectively. For the acute model, mice were injected with CCl<sub>4</sub> once and samples were taken at 24 h, 72 h, and 1 w. For the chronic model, mice received a regimen of semi-weekly injection of CCl<sub>4</sub> for 4 weeks. After this regimen, mice were sacrificed and samples were taken at 24 h, 72 h, and 2 w. The statistical results from single cell dataset of stem cell-derived human liver organoids were obtained from GSE207889 <sup><xref ref-type="bibr" rid="c78">78</xref></sup>.</p>
</sec>
<sec id="s4i">
<title>3D liver spheroid MASH model</title>
<p>3D liver spheroids were generated based on co-cultures of cryopreserved primary human hepatocytes (PHH) and liver non-parenchymal cells (NPC) as previously described <sup><xref ref-type="bibr" rid="c75">75</xref></sup>. Briefly, cells were seeded at a PHH:NPC ratio of 6:1 in 96-well ultra-low attachment plates (CLS7007-24EA Corning) with a total of 1500 cells/well in culture medium (William’s E medium containing 11 mM glucose, 100 nM dexamethasone, 10 μg/mL insulin, 5.5 mg/L transferrin, 6.7 μg/L selenite, 2 mM L-glutamine, 100 U/mL penicillin, 0.1 mg/mL streptomycin) supplemented with 10% FBS. After spheroid formation FBS was phased out and cells were maintained in medium supplemented with albumin-conjugated free-fatty acids (FFA) including 80μM palmitic acid and 80 μM oleic acid. At the end of the experiment, spheroids were collected for RNA extraction (Zymo R105). The elafibranor treatment protocol was described in the previous study <sup><xref ref-type="bibr" rid="c75">75</xref></sup>. Each experimental condition (control, MASH, and elafibranor treatment) was performed in quadruplicate.</p>
</sec>
</sec>

</body>
<back>
<sec id="s7" sec-type="data-availability">
<title>Data availability</title>
<p>All data are available within the manuscript, supplemental figures, and supplemental tables. RNA sequencing data to this article have been submitted to SRA (PRJNA1185558) and is deposited with GEO (GSE281797). Untargeted LC-HRMS data is deposited with Zenodo, including IDA data (DOI 10.5281/zenodo.14091962), SWATH data for the organic fraction (DOI 10.5281/zenodo.14096635), and SWATH data for the aqueous fraction (DOI 10.5281/zenodo.14096753, DOI 10.5281/zenodo.14136832). All clinical data, processed omics datasets, and code are available at <ext-link ext-link-type="uri" xlink:href="https://github.com/SLINGhub/MASLD_dual_omics">https://github.com/SLINGhub/MASLD_dual_omics</ext-link>.</p>
</sec>
<ack>
<title>Acknowledgements</title>
<p>We thank all present and past members of the Watt, Choi, Lauschke, and Kaldis laboratories for discussions, input, and support. P.K. thanks Åke Nilsson for discussions and suggestions.</p>
</ack>
<sec id="additional-info" sec-type="additional-information">
<title>Additional information</title>
<sec id="s8">
<title>Financial support statement</title>
<p>PK is supported in part by the Novo Nordisk Foundation (NNF24OC0092365), Swedish Research Council (2021-01331), the Swedish Cancer Society (Cancerfonden; 21-1566Pj and 24-3605Pj), the Crafoord Foundation (Ref. No. 20220628), the Swedish Foundation for Strategic Research Dnr IRC15-0067, and Swedish Research Council, Strategic Research Area EXODIAB, Dnr 2009-1039. LNZ is supported in part by the IngaBritt och Arne Lundbergs Forskningsstiftelse LU2020-0013, the Crafoord Foundation (Ref. No. 20210516, Ref. No. 20220582), Stiftelsen Längmanska kulturfonden (BA21-0148), and the Åke Wibergs Stiftelse. VML acknowledges support from the Swedish Research Council (2021-02801 and 2023-03015), the Ruth och Richard Julins Foundation for Gastroenterology (2021-00158), Knut and Alice Wallenberg Foundation (VC-2021-0026), by the SciLifeLab and Wallenberg National Program for Data-Driven Life Science (WASPDDLS22:006), a Novo Nordisk Pioneer Innovator Grant (NNF23OC0085944), the Robert Bosch Foundation, as well as the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 875510. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA, Ontario Institute for Cancer Research, Royal Institution for the Advancement of Learning McGill University, Kungliga Tekniska Hoegskolan, and Diamond Light Source Limited. HC is supported in part by Singapore Ministry of Education (T2EP202121-0016, T2EP20223-0010), National Research Foundation and Agency for Science, Technology and Research (I1901E0040), and National Medical Research Council (CG21APR1008). MJW is supported by the National Health and Medical Research Council of Australia (APP1162511). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</p>
</sec>
<sec id="s9">
<title>Author contributions</title>
<p>QZ*: designing research studies, conducting experiments, acquiring data, analyzing data, writing the manuscript</p>
<p>WD*: designing research studies, conducting experiments, acquiring data, analyzing data, writing the manuscript</p>
<p>RW*: analyzing data, writing the manuscript</p>
<p>YZ: conducting experiments, acquiring data, analyzing data UK: analyzing data, writing the manuscript</p>
<p>LNZ: analyzing data, writing the manuscript</p>
<p>HT: conducting experiments, acquiring data, analyzing data</p>
<p>SY: conducting experiments, acquiring data, analyzing data</p>
<p>MY: conducting experiments, acquiring data, analyzing data</p>
<p>YX: conducting experiments, acquiring data, analyzing data</p>
<p>YK: conducting experiments, acquiring data, analyzing data</p>
<p>SL: conducting experiments, acquiring data, analyzing data</p>
<p>RL: conducting experiments, acquiring data, analyzing data</p>
<p>GT: conducting experiments, acquiring data, analyzing data</p>
<p>PN: conducting experiments, acquiring data, analyzing data</p>
<p>PRB: providing reagents, cohort management</p>
<p>VMK: designing research studies, analyzing data, writing the manuscript, supervision, funding acquisition</p>
<p>HC: designing research studies, analyzing data, writing the manuscript, supervision, funding acquisition</p>
<p>MJW: designing research studies, analyzing data, writing the manuscript, supervision, funding acquisition</p>
<p>PK: designing research studies, analyzing data, writing the manuscript, supervision, funding acquisition, leading of collaboration</p>
<p>QZ, WD, and RW are co-first authors based on their contributions, which was writing original draft, LC-MS data acquisition and bioinformatic analysis of transcriptomic, metabolomic, and clinical data (QZ), organizing cohort samples, clinical parameters, managing, and LX-2 experiments (WD), and writing the original draft and analyzing data (RW).</p>
</sec>
    <glossary>
        <def-list>
            <title>Abbreviations</title>
            <def-item><term>ALT</term><def><p>Alanine aminotransferase</p></def></def-item>
            <def-item><term>AST</term><def><p>Aspartate aminotransferase</p></def></def-item>
            <def-item><term>ALP</term><def><p>Alkaline phosphatase</p></def></def-item>
            <def-item><term>CAR</term><def><p>Acylcarnitines</p></def></def-item>
            <def-item><term>CCl<sub>4</sub></term><def><p>Carbon tetrachloride</p></def></def-item>
            <def-item><term>Cer</term><def><p>Ceramide</p></def></def-item>
            <def-item><term>CM</term><def><p>Conditioned medium</p></def></def-item>
            <def-item><term>CYP</term><def><p>Cytochrome P</p></def></def-item>
            <def-item><term>DAG/DG</term><def><p>Diacylglycerol</p></def></def-item>
            <def-item><term>DDA</term><def><p>Data-dependent acquisition</p></def></def-item>
            <def-item><term>ECM</term><def><p>Extracellular matrix</p></def></def-item>
            <def-item><term>FBS</term><def><p>Fetal bovine serum</p></def></def-item>
            <def-item><term>FFA</term><def><p>Free-fatty acids</p></def></def-item>
            <def-item><term>FXR</term><def><p>Farnesoid X receptor</p></def></def-item>
            <def-item><term>GAP</term><def><p>GTPase-activating protein</p></def></def-item>
            <def-item><term>GEF</term><def><p>Guanine nucleotide exchange factor</p></def></def-item>
            <def-item><term>GGT</term><def><p>Gamma-glutamyltransferase</p></def></def-item>
            <def-item><term>GL</term><def><p>Glycerolipid</p></def></def-item>
            <def-item><term>GPL</term><def><p>Glycerophospholipid</p></def></def-item>
            <def-item><term>HSC</term><def><p>Hepatic stellate cell</p></def></def-item>
            <def-item><term>HILIC</term><def><p>Hydrophilic interaction liquid chromatography</p></def></def-item>
            <def-item><term>LD</term><def><p>Lipid droplet</p></def></def-item>
            <def-item><term>LNAPE</term><def><p>N-acyl-lysophosphatidylethanolamine</p></def></def-item>
            <def-item><term>LPC-O</term><def><p>Ether-linked lysophosphatidylcholine</p></def></def-item>
            <def-item><term>LPI</term><def><p>Ether-linked lysophosphatidylinositol</p></def></def-item>
            <def-item><term>LPS</term><def><p>Ether-linked lysophosphatidylserine</p></def></def-item>
            <def-item><term>LPC</term><def><p>Lysophosphatidylcholine</p></def></def-item>
            <def-item><term>LPE</term><def><p>Lysophosphatidylethanolamine</p></def></def-item>
            <def-item><term>MG</term><def><p>Monoacylglycerol</p></def></def-item>
            <def-item><term>MASH</term><def><p>Metabolic dysfunction-associated steatohepatitis</p></def></def-item>
            <def-item><term>MASLD</term><def><p>Metabolic dysfunction-associated steatotic liver disease</p></def></def-item>
            <def-item><term>NAS</term><def><p>NAFLD activity score</p></def></def-item>
            <def-item><term>NPC</term><def><p>Non-parenchymal cells</p></def></def-item>
            <def-item><term>NAE</term><def><p>N-acyl ethanolamines</p></def></def-item>
            <def-item><term>PCA</term><def><p>Principal component analysis</p></def></def-item>
            <def-item><term>PHH</term><def><p>Primary human hepatocytes</p></def></def-item>
            <def-item><term>PUFA</term><def><p>Polyunsaturated fatty acid</p></def></def-item>
            <def-item><term>PC</term><def><p>Phosphatidylcholine</p></def></def-item>
            <def-item><term>PC-O</term><def><p>Ether-linked phosphatidylcholine</p></def></def-item>
            <def-item><term>PE</term><def><p>Phosphatidylethanolamine</p></def></def-item>
            <def-item><term>PE-O</term><def><p>Ether-linked phosphatidylethanolamine</p></def></def-item>
            <def-item><term>PG</term><def><p>Phosphatidylglycerol</p></def></def-item>
            <def-item><term>PI</term><def><p>Phosphatidylinositol</p></def></def-item>
            <def-item><term>PS</term><def><p>Phosphatidylserine</p></def></def-item>
            <def-item><term>QC</term><def><p>Quality control</p></def></def-item>
            <def-item><term>RP</term><def><p>Reverse phase</p></def></def-item>
            <def-item><term>SM</term><def><p>Sphingomyelin</p></def></def-item>
            <def-item><term>SL</term><def><p>Sphingolipid</p></def></def-item>
            <def-item><term>SPB</term><def><p>Sphingoid base</p></def></def-item>
            <def-item><term>TAG/TG</term><def><p>Triacylglyceride</p></def></def-item>
            <def-item><term>TAG-O</term><def><p>Ether-linked triacylglycerol</p></def></def-item>
            <def-item><term>Vitamin E</term><def><p>Alpha-tocopherol</p></def></def-item>
        </def-list>
    </glossary>
</sec>
<sec id="additional-files" sec-type="supplementary-material">
<title>Additional files</title>
<supplementary-material id="supp1">
<label>Combined Supplementary text and data</label>
<media xlink:href="supplements/632747_file02.pdf"/>
</supplementary-material>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Miao</surname> <given-names>L</given-names></string-name>, <string-name><surname>Targher</surname> <given-names>G</given-names></string-name>, <string-name><surname>Byrne</surname> <given-names>CD</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Current status and future trends of the global burden of MASLD</article-title>. <source>Trends Endocrinol Metab</source> <year>2024</year>;<volume>35</volume>:<fpage>697</fpage>–<lpage>707</lpage>.</mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Riazi</surname> <given-names>K</given-names></string-name>, <string-name><surname>Azhari</surname> <given-names>H</given-names></string-name>, <string-name><surname>Charette</surname> <given-names>JH</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis</article-title>. <source>Lancet Gastroenterol Hepatol</source> <year>2022</year>;<volume>7</volume>:<fpage>851</fpage>–<lpage>861</lpage>.</mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Targher</surname> <given-names>G</given-names></string-name>, <string-name><surname>Byrne</surname> <given-names>CD</given-names></string-name>, <string-name><surname>Tilg</surname> <given-names>H</given-names></string-name></person-group>. <article-title>MASLD: a systemic metabolic disorder with cardiovascular and malignant complications</article-title>. <source>Gut</source> <year>2024</year>;<volume>73</volume>:<fpage>691</fpage>–<lpage>702</lpage>.</mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yki-Jarvinen</surname> <given-names>H</given-names></string-name></person-group>. <article-title>Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome</article-title>. <source>Lancet Diabetes Endocrinol</source> <year>2014</year>;<volume>2</volume>:<fpage>901</fpage>–<lpage>10</lpage>.</mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Angulo</surname> <given-names>P</given-names></string-name>, <string-name><surname>Kleiner</surname> <given-names>DE</given-names></string-name>, <string-name><surname>Dam-Larsen</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease</article-title>. <source>Gastroenterology</source> <year>2015</year>;<volume>149</volume>:<fpage>389</fpage>–<lpage>97.</lpage> </mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ekstedt</surname> <given-names>M</given-names></string-name>, <string-name><surname>Hagström</surname> <given-names>H</given-names></string-name>, <string-name><surname>Nasr</surname> <given-names>P</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up</article-title>. <source>Hepatology</source> <year>2015</year>;<volume>61</volume>:<fpage>1547</fpage>–<lpage>54</lpage>.</mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hagstrom</surname> <given-names>H</given-names></string-name>, <string-name><surname>Nasr</surname> <given-names>P</given-names></string-name>, <string-name><surname>Ekstedt</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD</article-title>. <source>J Hepatol</source> <year>2017</year>;<volume>67</volume>:<fpage>1265</fpage>–<lpage>1273</lpage>.</mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rodriguez</surname> <given-names>LA</given-names></string-name>, <string-name><surname>Schmittdiel</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>L</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease</article-title>. <source>JAMA Netw Open</source> <year>2024</year>;<volume>7</volume>:<fpage>e2421019</fpage>.</mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Feng</surname> <given-names>G</given-names></string-name>, <string-name><surname>Valenti</surname> <given-names>L</given-names></string-name>, <string-name><surname>Wong</surname> <given-names>VW</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease</article-title>. <source>Nat Rev Gastroenterol Hepatol</source> <year>2024</year>;<volume>21</volume>:<fpage>46</fpage>–<lpage>56</lpage>.</mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Eslam</surname> <given-names>M</given-names></string-name>, <string-name><surname>Newsome</surname> <given-names>PN</given-names></string-name>, <string-name><surname>Sarin</surname> <given-names>SK</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement</article-title>. <source>J Hepatol</source> <year>2020</year>;<volume>73</volume>:<fpage>202</fpage>–<lpage>209</lpage>.</mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Scoditti</surname> <given-names>E</given-names></string-name>, <string-name><surname>Sabatini</surname> <given-names>S</given-names></string-name>, <string-name><surname>Carli</surname> <given-names>F</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Hepatic glucose metabolism in the steatotic liver</article-title>. <source>Nat Rev Gastroenterol Hepatol</source> <year>2024</year>;<volume>21</volume>:<fpage>319</fpage>–<lpage>334</lpage>.</mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lambert</surname> <given-names>JE</given-names></string-name>, <string-name><surname>Ramos-Roman</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Browning</surname> <given-names>JD</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease</article-title>. <source>Gastroenterology</source> <year>2014</year>;<volume>146</volume>:<fpage>726</fpage>–<lpage>35</lpage>.</mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sakuma</surname> <given-names>I</given-names></string-name>, <string-name><surname>Gaspar</surname> <given-names>RC</given-names></string-name>, <string-name><surname>Nasiri</surname> <given-names>AR</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction-associated steatohepatitis</article-title>. <source>Proc Natl Acad Sci U S A</source> <year>2025</year>;<volume>122</volume>:<fpage>e2502978122</fpage>.</mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Koliaki</surname> <given-names>C</given-names></string-name>, <string-name><surname>Szendroedi</surname> <given-names>J</given-names></string-name>, <string-name><surname>Kaul</surname> <given-names>K</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis</article-title>. <source>Cell Metab</source> <year>2015</year>;<volume>21</volume>:<fpage>739</fpage>–<lpage>46</lpage>.</mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fromenty</surname> <given-names>B</given-names></string-name>, <string-name><surname>Roden</surname> <given-names>M</given-names></string-name></person-group>. <article-title>Mitochondrial alterations in fatty liver diseases</article-title>. <source>J Hepatol</source> <year>2023</year>;<volume>78</volume>:<fpage>415</fpage>–<lpage>429</lpage>.</mixed-citation></ref>
<ref id="c16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bril</surname> <given-names>F</given-names></string-name>, <string-name><surname>Barb</surname> <given-names>D</given-names></string-name>, <string-name><surname>Portillo-Sanchez</surname> <given-names>P</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease</article-title>. <source>Hepatology</source> <year>2017</year>;<volume>65</volume>:<fpage>1132</fpage>–<lpage>1144</lpage>.</mixed-citation></ref>
<ref id="c17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Younossi</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Anstee</surname> <given-names>QM</given-names></string-name>, <string-name><surname>Marietti</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention</article-title>. <source>Nat Rev Gastroenterol Hepatol</source> <year>2018</year>;<volume>15</volume>:<fpage>11</fpage>–<lpage>20</lpage>.</mixed-citation></ref>
<ref id="c18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vvedenskaya</surname> <given-names>O</given-names></string-name>, <string-name><surname>Rose</surname> <given-names>TD</given-names></string-name>, <string-name><surname>Knittelfelder</surname> <given-names>O</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Nonalcoholic fatty liver disease stratification by liver lipidomics</article-title>. <source>J Lipid Res</source> <year>2021</year>;<volume>62</volume>:<fpage>100104</fpage>.</mixed-citation></ref>
<ref id="c19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McGlinchey</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Govaere</surname> <given-names>O</given-names></string-name>, <string-name><surname>Geng</surname> <given-names>D</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease</article-title>. <source>JHEP Rep</source> <year>2022</year>;<volume>4</volume>:<fpage>100477</fpage>.</mixed-citation></ref>
<ref id="c20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Angulo</surname> <given-names>P</given-names></string-name>, <string-name><surname>Kleiner</surname> <given-names>DE</given-names></string-name>, <string-name><surname>Dam-Larsen</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease</article-title>. <source>Gastroenterology</source> <year>2015</year>;<volume>149</volume>:<fpage>389</fpage>–<lpage>97.</lpage> </mixed-citation></ref>
<ref id="c21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bataller</surname> <given-names>R</given-names></string-name>, <string-name><surname>Brenner</surname> <given-names>DA</given-names></string-name></person-group>. <article-title>Liver fibrosis</article-title>. <source>J Clin Invest</source> <year>2005</year>;<volume>115</volume>:<fpage>209</fpage>–<lpage>18</lpage>.</mixed-citation></ref>
<ref id="c22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Subramanian</surname> <given-names>P</given-names></string-name>, <string-name><surname>Hampe</surname> <given-names>J</given-names></string-name>, <string-name><surname>Tacke</surname> <given-names>F</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Fibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD)</article-title>. <source>Int J Mol Sci</source> <year>2022</year>;<volume>23</volume>:<fpage>6996</fpage>.</mixed-citation></ref>
<ref id="c23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Powell</surname> <given-names>EE</given-names></string-name>, <string-name><surname>Wong</surname> <given-names>VW</given-names></string-name>, <string-name><surname>Rinella</surname> <given-names>M</given-names></string-name></person-group>. <article-title>Non-alcoholic fatty liver disease</article-title>. <source>Lancet</source> <year>2021</year>;<volume>397</volume>:<fpage>2212</fpage>–<lpage>2224</lpage>.</mixed-citation></ref>
    <ref id="c24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>European Association for the Study of the Liver</collab>, <collab>European Association for the Study of Diabetes</collab>, <collab>European Association for the Study of Obesity</collab></person-group> <article-title>EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)</article-title>. <source>J Hepatol</source> <year>2024</year>;<volume>81</volume>:<fpage>492</fpage>–<lpage>542</lpage>.</mixed-citation></ref>
<ref id="c25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rinella</surname> <given-names>ME</given-names></string-name>, <string-name><surname>Neuschwander-Tetri</surname> <given-names>BA</given-names></string-name>, <string-name><surname>Siddiqui</surname> <given-names>MS</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease</article-title>. <source>Hepatology</source> <year>2023</year>;<volume>77</volume>:<fpage>1797</fpage>–<lpage>1835</lpage>.</mixed-citation></ref>
<ref id="c26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hoang</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Oseini</surname> <given-names>A</given-names></string-name>, <string-name><surname>Feaver</surname> <given-names>RE</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Gene Expression Predicts Histological Severity and Reveals Distinct Molecular Profiles of Nonalcoholic Fatty Liver Disease</article-title>. <source>Sci Rep</source> <year>2019</year>;<volume>9</volume>:<fpage>12541</fpage>.</mixed-citation></ref>
<ref id="c27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Govaere</surname> <given-names>O</given-names></string-name>, <string-name><surname>Cockell</surname> <given-names>S</given-names></string-name>, <string-name><surname>Tiniakos</surname> <given-names>D</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis</article-title>. <source>Sci Transl Med</source> <year>2020</year>;<volume>12</volume>:<fpage>eaba4448</fpage>.</mixed-citation></ref>
<ref id="c28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Govaere</surname> <given-names>O</given-names></string-name>, <string-name><surname>Hasoon</surname> <given-names>M</given-names></string-name>, <string-name><surname>Alexander</surname> <given-names>L</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures</article-title>. <source>Nat Metab</source> <year>2023</year>;<volume>5</volume>:<fpage>572</fpage>–<lpage>578</lpage>.</mixed-citation></ref>
<ref id="c29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Roumans</surname> <given-names>KHM</given-names></string-name>, <string-name><surname>Lindeboom</surname> <given-names>L</given-names></string-name>, <string-name><surname>Veeraiah</surname> <given-names>P</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Hepatic saturated fatty acid fraction is associated with de novo lipogenesis and hepatic insulin resistance</article-title>. <source>Nat Commun</source> <year>2020</year>;<volume>11</volume>:<fpage>1891</fpage>.</mixed-citation></ref>
<ref id="c30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname> <given-names>D</given-names></string-name>, <string-name><surname>Wei</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Pagliassotti</surname> <given-names>MJ</given-names></string-name></person-group>. <article-title>Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis</article-title>. <source>Endocrinology</source> <year>2006</year>;<volume>147</volume>:<fpage>943</fpage>–<lpage>51</lpage>.</mixed-citation></ref>
    <ref id="c31"><label>31.</label><mixed-citation publication-type="preprint"><person-group person-group-type="author"><string-name><surname>Lee</surname> <given-names>S</given-names></string-name>, <string-name><surname>Bang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Learning Massive-scale Partial Correlation Networks in Clinical Multi-omics Studies with HP-ACCORD</article-title>. <source>arXiv</source>. <year>2024</year></mixed-citation></ref>
<ref id="c32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Qadri</surname> <given-names>SF</given-names></string-name>, <string-name><surname>Bian</surname> <given-names>H</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>A metabolome-derived score predicts metabolic dysfunction-associated steatohepatitis and mortality from liver disease</article-title>. <source>J Hepatol</source> <year>2025</year>;<volume>82</volume>:<fpage>781</fpage>–<lpage>793</lpage>.</mixed-citation></ref>
<ref id="c33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lahdou</surname> <given-names>I</given-names></string-name>, <string-name><surname>Sadeghi</surname> <given-names>M</given-names></string-name>, <string-name><surname>Oweira</surname> <given-names>H</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Increased serum levels of quinolinic acid indicate enhanced severity of hepatic dysfunction in patients with liver cirrhosis</article-title>. <source>Hum Immunol</source> <year>2013</year>;<volume>74</volume>:<fpage>60</fpage>–<lpage>6</lpage>.</mixed-citation></ref>
<ref id="c34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gou</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Li</surname> <given-names>A</given-names></string-name>, <string-name><surname>Dong</surname> <given-names>X</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Lactate transporter MCT4 regulates the hub genes for lipid metabolism and inflammation to attenuate intracellular lipid accumulation in non-alcoholic fatty liver disease</article-title>. <source>Genes Dis</source> <year>2025</year>;<volume>12</volume>:<fpage>101554</fpage>.</mixed-citation></ref>
<ref id="c35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tan</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Deng</surname> <given-names>S</given-names></string-name>, <string-name><surname>Xiong</surname> <given-names>L</given-names></string-name></person-group>. <article-title>Role of Kynurenine and Its Derivatives in Liver Diseases: Recent Advances and Future Clinical Perspectives</article-title>. <source>Int J Mol Sci</source> <year>2025</year>;<volume>26</volume>.</mixed-citation></ref>
<ref id="c36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mashek</surname> <given-names>DG</given-names></string-name></person-group>. <article-title>Hepatic lipid droplets: A balancing act between energy storage and metabolic dysfunction in NAFLD</article-title>. <source>Mol Metab</source> <year>2021</year>;<volume>50</volume>:<fpage>101115</fpage>.</mixed-citation></ref>
<ref id="c37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Holdaway</surname> <given-names>CM</given-names></string-name>, <string-name><surname>Leonard</surname> <given-names>KA</given-names></string-name>, <string-name><surname>Nelson</surname> <given-names>R</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Alterations in phosphatidylethanolamine metabolism impacts hepatocellular lipid storage, energy homeostasis, and proliferation</article-title>. <source>Biochim Biophys Acta Mol Cell Biol Lipids</source> <year>2025</year>;<volume>1870</volume>:<fpage>159608</fpage>.</mixed-citation></ref>
<ref id="c38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>van der Veen</surname> <given-names>JN</given-names></string-name>, <string-name><surname>Lingrell</surname> <given-names>S</given-names></string-name>, <string-name><surname>Vance</surname> <given-names>DE</given-names></string-name></person-group>. <article-title>The membrane lipid phosphatidylcholine is an unexpected source of triacylglycerol in the liver</article-title>. <source>J Biol Chem</source> <year>2012</year>;<volume>287</volume>:<fpage>23418</fpage>–<lpage>26</lpage>.</mixed-citation></ref>
<ref id="c39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Dos</given-names> <surname>Santos LRB</surname></string-name>, <string-name><surname>Fleming</surname> <given-names>I</given-names></string-name></person-group>. <article-title>Role of cytochrome P450-derived, polyunsaturated fatty acid mediators in diabetes and the metabolic syndrome</article-title>. <source>Prostaglandins Other Lipid Mediat</source> <year>2020</year>;<volume>148</volume>:<fpage>106407</fpage>.</mixed-citation></ref>
<ref id="c40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hajeyah</surname> <given-names>AA</given-names></string-name>, <string-name><surname>Griffiths</surname> <given-names>WJ</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>The Biosynthesis of Enzymatically Oxidized Lipids</article-title>. <source>Front Endocrinol</source> <year>2020</year>;<volume>11</volume>:<fpage>591819</fpage>.</mixed-citation></ref>
<ref id="c41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Albaugh</surname> <given-names>VL</given-names></string-name>, <string-name><surname>Mukherjee</surname> <given-names>K</given-names></string-name>, <string-name><surname>Barbul</surname> <given-names>A</given-names></string-name></person-group>. <article-title>Proline Precursors and Collagen Synthesis: Biochemical Challenges of Nutrient Supplementation and Wound Healing</article-title>. <source>J Nutr</source> <year>2017</year>;<volume>147</volume>:<fpage>2011</fpage>–<lpage>2017</lpage>.</mixed-citation></ref>
<ref id="c42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>de Paz-Lugo</surname> <given-names>P</given-names></string-name>, <string-name><surname>Lupianez</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Melendez-Hevia</surname> <given-names>E</given-names></string-name></person-group>. <article-title>High glycine concentration increases collagen synthesis by articular chondrocytes in vitro: acute glycine deficiency could be an important cause of osteoarthritis</article-title>. <source>Amino Acids</source> <year>2018</year>;<volume>50</volume>:<fpage>1357</fpage>–<lpage>1365</lpage>.</mixed-citation></ref>
<ref id="c43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schnabl</surname> <given-names>B</given-names></string-name>, <string-name><surname>Damman</surname> <given-names>CJ</given-names></string-name>, <string-name><surname>Carr</surname> <given-names>RM</given-names></string-name></person-group>. <article-title>Metabolic dysfunction-associated steatotic liver disease and the gut microbiome: pathogenic insights and therapeutic innovations</article-title>. <source>J Clin Invest</source> <year>2025</year>;<volume>135</volume>.</mixed-citation></ref>
<ref id="c44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yanko</surname> <given-names>R</given-names></string-name>, <string-name><surname>Levashov</surname> <given-names>M</given-names></string-name>, <string-name><surname>Chaka</surname> <given-names>OG</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Tryptophan Prevents the Development of Non-Alcoholic Fatty Liver Disease</article-title>. <source>Diabetes Metab Syndr Obes</source> <year>2023</year>;<volume>16</volume>:<fpage>4195</fpage>–<lpage>4204</lpage>.</mixed-citation></ref>
<ref id="c45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Arto</surname> <given-names>C</given-names></string-name>, <string-name><surname>Rusu</surname> <given-names>EC</given-names></string-name>, <string-name><surname>Clavero-Mestres</surname> <given-names>H</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Metabolic profiling of tryptophan pathways: Implications for obesity and metabolic dysfunction-associated steatotic liver disease</article-title>. <source>Eur J Clin Invest</source> <year>2024</year>;<volume>54</volume>:<fpage>e14279</fpage>.</mixed-citation></ref>
<ref id="c46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Walker</surname> <given-names>AK</given-names></string-name></person-group>. <article-title>1-Carbon Cycle Metabolites Methylate Their Way to Fatty Liver</article-title>. <source>Trends Endocrinol Metab</source> <year>2017</year>;<volume>28</volume>:<fpage>63</fpage>–<lpage>72</lpage>.</mixed-citation></ref>
<ref id="c47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Varela-Rey</surname> <given-names>M</given-names></string-name>, <string-name><surname>Martinez-Lopez</surname> <given-names>N</given-names></string-name>, <string-name><surname>Fernandez-Ramos</surname> <given-names>D</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Fatty liver and fibrosis in glycine N-methyltransferase knockout mice is prevented by nicotinamide</article-title>. <source>Hepatology</source> <year>2010</year>;<volume>52</volume>:<fpage>105</fpage>–<lpage>14</lpage>.</mixed-citation></ref>
<ref id="c48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Robinson</surname> <given-names>AE</given-names></string-name>, <string-name><surname>Binek</surname> <given-names>A</given-names></string-name>, <string-name><surname>Ramani</surname> <given-names>K</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Hyperphosphorylation of hepatic proteome characterizes nonalcoholic fatty liver disease in S-adenosylmethionine deficiency</article-title>. <source>iScience</source> <year>2023</year>;<volume>26</volume>:<fpage>105987</fpage>.</mixed-citation></ref>
<ref id="c49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Alarcon-Vila</surname> <given-names>C</given-names></string-name>, <string-name><surname>Insausti-Urkia</surname> <given-names>N</given-names></string-name>, <string-name><surname>Torres</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Dietary and genetic disruption of hepatic methionine metabolism induce acid sphingomyelinase to promote steatohepatitis</article-title>. <source>Redox Biol</source> <year>2023</year>;<volume>59</volume>:<issue>102596</issue>.</mixed-citation></ref>
<ref id="c50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Matthews</surname> <given-names>RP</given-names></string-name>, <string-name><surname>Lorent</surname> <given-names>K</given-names></string-name>, <string-name><surname>Manoral-Mobias</surname> <given-names>R</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>TNFalpha-dependent hepatic steatosis and liver degeneration caused by mutation of zebrafish S-adenosylhomocysteine hydrolase</article-title>. <source>Development</source> <year>2009</year>;<volume>136</volume>:<fpage>865</fpage>–<lpage>75</lpage>.</mixed-citation></ref>
<ref id="c51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sousa</surname> <given-names>AP</given-names></string-name>, <string-name><surname>Cunha</surname> <given-names>DM</given-names></string-name>, <string-name><surname>Franco</surname> <given-names>C</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Which Role Plays 2-Hydroxybutyric Acid on Insulin Resistance?</article-title> <source>Metabolites</source> <year>2021</year>;<volume>11</volume>.</mixed-citation></ref>
<ref id="c52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Knottnerus</surname> <given-names>SJG</given-names></string-name>, <string-name><surname>Bleeker</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Wust</surname> <given-names>RCI</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Disorders of mitochondrial long-chain fatty acid oxidation and the carnitine shuttle</article-title>. <source>Rev Endocr Metab Disord</source> <year>2018</year>;<volume>19</volume>:<fpage>93</fpage>–<lpage>106</lpage>.</mixed-citation></ref>
<ref id="c53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Houten</surname> <given-names>SM</given-names></string-name>, <string-name><surname>Violante</surname> <given-names>S</given-names></string-name>, <string-name><surname>Ventura</surname> <given-names>FV</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>The Biochemistry and Physiology of Mitochondrial Fatty Acid beta-Oxidation and Its Genetic Disorders</article-title>. <source>Annu Rev Physiol</source> <year>2016</year>;<volume>78</volume>:<fpage>23</fpage>–<lpage>44</lpage>.</mixed-citation></ref>
<ref id="c54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rath</surname> <given-names>S</given-names></string-name>, <string-name><surname>Sharma</surname> <given-names>R</given-names></string-name>, <string-name><surname>Gupta</surname> <given-names>R</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>MitoCarta3.0: an updated mitochondrial proteome now with sub-organelle localization and pathway annotations</article-title>. <source>Nucleic Acids Res</source> <year>2021</year>;<volume>49</volume>:<fpage>D1541</fpage>–<lpage>D1547</lpage>.</mixed-citation></ref>
<ref id="c55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Trivedi</surname> <given-names>P</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>S</given-names></string-name>, <string-name><surname>Friedman</surname> <given-names>SL</given-names></string-name></person-group>. <article-title>The Power of Plasticity-Metabolic Regulation of Hepatic Stellate Cells</article-title>. <source>Cell Metab</source> <year>2021</year>;<volume>33</volume>:<fpage>242</fpage>–<lpage>257</lpage>.</mixed-citation></ref>
<ref id="c56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Martinez-Lopez</surname> <given-names>N</given-names></string-name>, <string-name><surname>Singh</surname> <given-names>R</given-names></string-name></person-group>. <article-title>Autophagy and Lipid Droplets in the Liver</article-title>. <source>Annu Rev Nutr</source> <year>2015</year>;<volume>35</volume>:<fpage>215</fpage>–<lpage>37</lpage>.</mixed-citation></ref>
<ref id="c57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xie</surname> <given-names>C</given-names></string-name>, <string-name><surname>Woollett</surname> <given-names>LA</given-names></string-name>, <string-name><surname>Turley</surname> <given-names>SD</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Fatty acids differentially regulate hepatic cholesteryl ester formation and incorporation into lipoproteins in the liver of the mouse</article-title>. <source>J Lipid Res</source> <year>2002</year>;<volume>43</volume>:<fpage>1508</fpage>–<lpage>19</lpage>.</mixed-citation></ref>
<ref id="c58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Min</surname> <given-names>HK</given-names></string-name>, <string-name><surname>Kapoor</surname> <given-names>A</given-names></string-name>, <string-name><surname>Fuchs</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease</article-title>. <source>Cell Metab</source> <year>2012</year>;<volume>15</volume>:<fpage>665</fpage>–<lpage>74</lpage>.</mixed-citation></ref>
<ref id="c59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kang</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>A</given-names></string-name></person-group>. <article-title>Curcumin eliminates oxidized LDL roles in activating hepatic stellate cells by suppressing gene expression of lectin-like oxidized LDL receptor-1</article-title>. <source>Lab Invest</source> <year>2009</year>;<volume>89</volume>:<fpage>1275</fpage>–<lpage>90</lpage>.</mixed-citation></ref>
<ref id="c60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tuohetahuntila</surname> <given-names>M</given-names></string-name>, <string-name><surname>Molenaar</surname> <given-names>MR</given-names></string-name>, <string-name><surname>Spee</surname> <given-names>B</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Lysosome-mediated degradation of a distinct pool of lipid droplets during hepatic stellate cell activation</article-title>. <source>J Biol Chem</source> <year>2017</year>;<volume>292</volume>:<fpage>12436</fpage>–<lpage>12448</lpage>.</mixed-citation></ref>
<ref id="c61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bordi</surname> <given-names>M</given-names></string-name>, <string-name><surname>De Cegli</surname> <given-names>R</given-names></string-name>, <string-name><surname>Testa</surname> <given-names>B</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>A gene toolbox for monitoring autophagy transcription</article-title>. <source>Cell Death Dis</source> <year>2021</year>;<volume>12</volume>:<fpage>1044</fpage>.</mixed-citation></ref>
<ref id="c62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Singh</surname> <given-names>R</given-names></string-name>, <string-name><surname>Kaushik</surname> <given-names>S</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Autophagy regulates lipid metabolism</article-title>. <source>Nature</source> <year>2009</year>;<volume>458</volume>:<fpage>1131</fpage>–<lpage>5</lpage>.</mixed-citation></ref>
<ref id="c63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>MacParland</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Ma</surname> <given-names>XZ</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations</article-title>. <source>Nat Commun</source> <year>2018</year>;<volume>9</volume>:<fpage>4383</fpage>.</mixed-citation></ref>
<ref id="c64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Fan</surname> <given-names>W</given-names></string-name>, <string-name><surname>Link</surname> <given-names>F</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Transforming growth factor beta latency: A mechanism of cytokine storage and signalling regulation in liver homeostasis and disease</article-title>. <source>JHEP Rep</source> <year>2022</year>;<volume>4</volume>:<fpage>100397</fpage>.</mixed-citation></ref>
<ref id="c65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wen</surname> <given-names>X</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Bai</surname> <given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>LOXL2, a copper-dependent monoamine oxidase, activates lung fibroblasts through the TGF-beta/Smad pathway</article-title>. <source>Int J Mol Med</source> <year>2018</year>;<volume>42</volume>:<fpage>3530</fpage>–<lpage>3541</lpage>.</mixed-citation></ref>
<ref id="c66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Munger</surname> <given-names>JS</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>X</given-names></string-name>, <string-name><surname>Kawakatsu</surname> <given-names>H</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis</article-title>. <source>Cell</source> <year>1999</year>;<volume>96</volume>:<fpage>319</fpage>–<lpage>28</lpage>.</mixed-citation></ref>
<ref id="c67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kisseleva</surname> <given-names>T</given-names></string-name>, <string-name><surname>Brenner</surname> <given-names>D</given-names></string-name></person-group>. <article-title>Molecular and cellular mechanisms of liver fibrosis and its regression</article-title>. <source>Nat Rev Gastroenterol Hepatol</source> <year>2021</year>;<volume>18</volume>:<fpage>151</fpage>–<lpage>166</lpage>.</mixed-citation></ref>
<ref id="c68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Massague</surname> <given-names>J</given-names></string-name>, <string-name><surname>Sheppard</surname> <given-names>D</given-names></string-name></person-group>. <article-title>TGF-beta signaling in health and disease</article-title>. <source>Cell</source> <year>2023</year>;<volume>186</volume>:<fpage>4007</fpage>–<lpage>4037</lpage>.</mixed-citation></ref>
<ref id="c69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Go</surname> <given-names>CD</given-names></string-name>, <string-name><surname>Knight</surname> <given-names>JDR</given-names></string-name>, <string-name><surname>Rajasekharan</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>A proximity-dependent biotinylation map of a human cell</article-title>. <source>Nature</source> <year>2021</year>;<volume>595</volume>:<fpage>120</fpage>–<lpage>124</lpage>.</mixed-citation></ref>
<ref id="c70"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Razick</surname> <given-names>S</given-names></string-name>, <string-name><surname>Magklaras</surname> <given-names>G</given-names></string-name>, <string-name><surname>Donaldson</surname> <given-names>IM</given-names></string-name></person-group>. <article-title>iRefIndex: a consolidated protein interaction database with provenance</article-title>. <source>BMC Bioinformatics</source> <year>2008</year>;<volume>9</volume>:<fpage>405</fpage>.</mixed-citation></ref>
<ref id="c71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huttlin</surname> <given-names>EL</given-names></string-name>, <string-name><surname>Bruckner</surname> <given-names>RJ</given-names></string-name>, <string-name><surname>Paulo</surname> <given-names>JA</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Architecture of the human interactome defines protein communities and disease networks</article-title>. <source>Nature</source> <year>2017</year>;<volume>545</volume>:<fpage>505</fpage>–<lpage>509</lpage>.</mixed-citation></ref>
<ref id="c72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bell</surname> <given-names>CC</given-names></string-name>, <string-name><surname>Hendriks</surname> <given-names>DF</given-names></string-name>, <string-name><surname>Moro</surname> <given-names>SM</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease</article-title>. <source>Sci Rep</source> <year>2016</year>;<volume>6</volume>:<fpage>25187</fpage>.</mixed-citation></ref>
<ref id="c73"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vorrink</surname> <given-names>SU</given-names></string-name>, <string-name><surname>Ullah</surname> <given-names>S</given-names></string-name>, <string-name><surname>Schmidt</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Endogenous and xenobiotic metabolic stability of primary human hepatocytes in long-term 3D spheroid cultures revealed by a combination of targeted and untargeted metabolomics</article-title>. <source>FASEB J</source> <year>2017</year>;<volume>31</volume>:<fpage>2696</fpage>–<lpage>2708</lpage>.</mixed-citation></ref>
<ref id="c74"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kemas</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Youhanna</surname> <given-names>S</given-names></string-name>, <string-name><surname>Zandi Shafagh</surname> <given-names>R</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Insulin-dependent glucose consumption dynamics in 3D primary human liver cultures measured by a sensitive and specific glucose sensor with nanoliter input volume</article-title>. <source>FASEB J</source> <year>2021</year>;<volume>35</volume>:<fpage>e21305</fpage>.</mixed-citation></ref>
<ref id="c75"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Youhanna</surname> <given-names>S</given-names></string-name>, <string-name><surname>Kemas</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Wright</surname> <given-names>SC</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Chemogenomic Screening in a Patient-Derived 3D Fatty Liver Disease Model Reveals the CHRM1-TRPM8 Axis as a Novel Module for Targeted Intervention</article-title>. <source>Adv Sci</source> <year>2025</year>;<volume>12</volume>:<fpage>e2407572</fpage>.</mixed-citation></ref>
<ref id="c76"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ratziu</surname> <given-names>V</given-names></string-name>, <string-name><surname>Harrison</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Francque</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-alpha and -delta, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening</article-title>. <source>Gastroenterology</source> <year>2016</year>;<volume>150</volume>:<fpage>1147</fpage>–<lpage>1159.</lpage> </mixed-citation></ref>
<ref id="c77"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>De Smet</surname> <given-names>V</given-names></string-name>, <string-name><surname>Eysackers</surname> <given-names>N</given-names></string-name>, <string-name><surname>Merens</surname> <given-names>V</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Initiation of hepatic stellate cell activation extends into chronic liver disease</article-title>. <source>Cell Death Dis</source> <year>2021</year>;<volume>12</volume>:<fpage>1110</fpage>.</mixed-citation></ref>
<ref id="c78"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hess</surname> <given-names>A</given-names></string-name>, <string-name><surname>Gentile</surname> <given-names>SD</given-names></string-name>, <string-name><surname>Ben Saad</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Single-cell transcriptomics stratifies organoid models of metabolic dysfunction-associated steatotic liver disease</article-title>. <source>EMBO J</source> <year>2023</year>;<volume>42</volume>:<fpage>e113898</fpage>.</mixed-citation></ref>
<ref id="c79"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Haag</surname> <given-names>M</given-names></string-name>, <string-name><surname>Winter</surname> <given-names>S</given-names></string-name>, <string-name><surname>Kemas</surname> <given-names>AM</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Circulating metabolite signatures indicate differential gut-liver crosstalk in lean and obese MASLD</article-title>. <source>JCI Insight</source> <year>2025</year>;<volume>10</volume>.</mixed-citation></ref>
<ref id="c80"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Barr</surname> <given-names>J</given-names></string-name>, <string-name><surname>Caballeria</surname> <given-names>J</given-names></string-name>, <string-name><surname>Martinez-Arranz</surname> <given-names>I</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression</article-title>. <source>J Proteome Res</source> <year>2012</year>;<volume>11</volume>:<fpage>2521</fpage>–<lpage>32</lpage>.</mixed-citation></ref>
<ref id="c81"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Leszczynska</surname> <given-names>A</given-names></string-name>, <string-name><surname>Stoess</surname> <given-names>C</given-names></string-name>, <string-name><surname>Sung</surname> <given-names>H</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Extracellular Vesicles as Therapeutic and Diagnostic Tools for Chronic Liver Diseases</article-title>. <source>Biomedicines</source> <year>2023</year>;<volume>11</volume>:<fpage>2808</fpage>.</mixed-citation></ref>
<ref id="c82"><label>82.</label><mixed-citation publication-type="preprint"><person-group person-group-type="author"><string-name><surname>Liu</surname> <given-names>J</given-names></string-name>, <string-name><surname>Hu</surname> <given-names>S</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>L</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Profiling the genome and proteome of metabolic dysfunction-associated steatotic liver disease identifies potential therapeutic targets</article-title>. <source>medRxiv</source>. <year>2023</year>:DOI: <pub-id pub-id-type="doi">10.1101/2023.11.30.23299247</pub-id>.</mixed-citation></ref>
<ref id="c83"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Radosavljevic</surname> <given-names>T</given-names></string-name>, <string-name><surname>Brankovic</surname> <given-names>M</given-names></string-name>, <string-name><surname>Samardzic</surname> <given-names>J</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Altered Mitochondrial Function in MASLD: Key Features and Promising Therapeutic Approaches</article-title>. <source>Antioxidants</source> <year>2024</year>;<volume>13</volume>:<fpage>906</fpage>.</mixed-citation></ref>
    <ref id="c84"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Saliba-Gustafsson</surname> <given-names>P</given-names></string-name>, <string-name><surname>Justesen</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Ranta</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>A functional genomic framework to elucidate novel causal metabolic dysfunction-associated fatty liver disease genes</article-title>. <source>Hepatology</source> <year>2024</year>:: in press.</mixed-citation></ref>
<ref id="c85"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Scorletti</surname> <given-names>E</given-names></string-name>, <string-name><surname>Carr</surname> <given-names>RM</given-names></string-name></person-group>. <article-title>A new perspective on NAFLD: Focusing on lipid droplets</article-title>. <source>J Hepatol</source> <year>2022</year>;<volume>76</volume>:<fpage>934</fpage>–<lpage>945</lpage>.</mixed-citation></ref>
<ref id="c86"><label>86.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Van Woerkom</surname> <given-names>A</given-names></string-name>, <string-name><surname>Harney</surname> <given-names>DJ</given-names></string-name>, <string-name><surname>Nagarajan</surname> <given-names>SR</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Hepatic lipid droplet-associated proteome changes distinguish dietary-induced fatty liver from glucose tolerance in male mice</article-title>. <source>Am J Physiol Endocrinol Metab</source> <year>2024</year>;<volume>326</volume>:<fpage>E842</fpage>–<lpage>E855</lpage>.</mixed-citation></ref>
<ref id="c87"><label>87.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Carr</surname> <given-names>RM</given-names></string-name>, <string-name><surname>Patel</surname> <given-names>RT</given-names></string-name>, <string-name><surname>Rao</surname> <given-names>V</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Reduction of TIP47 improves hepatic steatosis and glucose homeostasis in mice</article-title>. <source>Am J Physiol Regul Integr Comp Physiol</source> <year>2012</year>;<volume>302</volume>:<fpage>R996</fpage>–<lpage>1003</lpage>.</mixed-citation></ref>
<ref id="c88"><label>88.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Babiy</surname> <given-names>B</given-names></string-name>, <string-name><surname>Ramos-Molina</surname> <given-names>B</given-names></string-name>, <string-name><surname>Ocana</surname> <given-names>L</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Dihydrosphingolipids are associated with steatosis and increased fibrosis damage in non-alcoholic fatty liver disease</article-title>. <source>Biochim Biophys Acta Mol Cell Biol Lipids</source> <year>2023</year>;<volume>1868</volume>:<fpage>159318</fpage>.</mixed-citation></ref>
<ref id="c89"><label>89.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ooi</surname> <given-names>GJ</given-names></string-name>, <string-name><surname>Meikle</surname> <given-names>PJ</given-names></string-name>, <string-name><surname>Huynh</surname> <given-names>K</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis</article-title>. <source>J Hepatol</source> <year>2021</year>;<volume>75</volume>:<fpage>524</fpage>–<lpage>535</lpage>.</mixed-citation></ref>
<ref id="c90"><label>90.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wei</surname> <given-names>W</given-names></string-name>, <string-name><surname>Lyu</surname> <given-names>X</given-names></string-name>, <string-name><surname>Markhard</surname> <given-names>AL</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>PTER is a N-acetyltaurine hydrolase that regulates feeding and obesity</article-title>. <source>Nature</source> <year>2024</year>;<volume>633</volume>:<fpage>182</fpage>–<lpage>188</lpage>.</mixed-citation></ref>
<ref id="c91"><label>91.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Al-Baiaty</surname> <given-names>FDR</given-names></string-name>, <string-name><surname>Ismail</surname> <given-names>A</given-names></string-name>, <string-name><surname>Abdul Latiff</surname> <given-names>Z</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Possible Hepatoprotective Effect of Tocotrienol-Rich Fraction Vitamin E in Non-alcoholic Fatty Liver Disease in Obese Children and Adolescents</article-title>. <source>Front Pediatr</source> <year>2021</year>;<volume>9</volume>:<fpage>667247</fpage>.</mixed-citation></ref>
<ref id="c92"><label>92.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Arroyave-Ospina</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Geng</surname> <given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Role of Oxidative Stress in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Implications for Prevention and Therapy</article-title>. <source>Antioxidants</source> <year>2021</year>;<volume>10</volume>:<fpage>174</fpage>.</mixed-citation></ref>
<ref id="c93"><label>93.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Aggarwal</surname> <given-names>S</given-names></string-name>, <string-name><surname>Yadav</surname> <given-names>V</given-names></string-name>, <string-name><surname>Maiwall</surname> <given-names>R</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Metabolomic analysis shows dysregulation in amino acid and NAD+ metabolism in palmitate treated hepatocytes and plasma of non-alcoholic fatty liver disease spectrum</article-title>. <source>Biochem Biophys Res Commun</source> <year>2023</year>;<volume>643</volume>:<fpage>129</fpage>–<lpage>138</lpage>.</mixed-citation></ref>
<ref id="c94"><label>94.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xue</surname> <given-names>C</given-names></string-name>, <string-name><surname>Li</surname> <given-names>G</given-names></string-name>, <string-name><surname>Zheng</surname> <given-names>Q</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Tryptophan metabolism in health and disease</article-title>. <source>Cell Metab</source> <year>2023</year>;<volume>35</volume>:<fpage>1304</fpage>–<lpage>1326</lpage>.</mixed-citation></ref>
<ref id="c95"><label>95.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gual</surname> <given-names>P</given-names></string-name>, <string-name><surname>Gilgenkrantz</surname> <given-names>H</given-names></string-name>, <string-name><surname>Lotersztajn</surname> <given-names>S</given-names></string-name></person-group>. <article-title>Autophagy in chronic liver diseases: the two faces of Janus</article-title>. <source>Am J Physiol Cell Physiol</source> <year>2017</year>;<volume>312</volume>:<fpage>C263</fpage>–<lpage>C273</lpage>.</mixed-citation></ref>
<ref id="c96"><label>96.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Adeva-Andany</surname> <given-names>MM</given-names></string-name>, <string-name><surname>Carneiro-Freire</surname> <given-names>N</given-names></string-name>, <string-name><surname>Seco-Filgueira</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Mitochondrial beta-oxidation of saturated fatty acids in humans</article-title>. <source>Mitochondrion</source> <year>2019</year>;<volume>46</volume>:<fpage>73</fpage>–<lpage>90</lpage>.</mixed-citation></ref>
<ref id="c97"><label>97.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gray</surname> <given-names>JL</given-names></string-name>, <string-name><surname>von Delft</surname> <given-names>F</given-names></string-name>, <string-name><surname>Brennan</surname> <given-names>PE</given-names></string-name></person-group>. <article-title>Targeting the Small GTPase Superfamily through Their Regulatory Proteins</article-title>. <source>Angew Chem Int Ed Engl</source> <year>2020</year>;<volume>59</volume>:<fpage>6342</fpage>–<lpage>6366</lpage>.</mixed-citation></ref>
<ref id="c98"><label>98.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bos</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Rehmann</surname> <given-names>H</given-names></string-name>, <string-name><surname>Wittinghofer</surname> <given-names>A</given-names></string-name></person-group>. <article-title>GEFs and GAPs: critical elements in the control of small G proteins</article-title>. <source>Cell</source> <year>2007</year>;<volume>129</volume>:<fpage>865</fpage>–<lpage>77</lpage>.</mixed-citation></ref>
<ref id="c99"><label>99.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname> <given-names>H</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>SH</given-names></string-name>, <string-name><surname>Sousa-Lima</surname> <given-names>I</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Rho-kinase/AMPK axis regulates hepatic lipogenesis during overnutrition</article-title>. <source>J Clin Invest</source> <year>2018</year>;<volume>128</volume>:<fpage>5335</fpage>–<lpage>5350</lpage>.</mixed-citation></ref>
<ref id="c100"><label>100.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schwerbel</surname> <given-names>K</given-names></string-name>, <string-name><surname>Kamitz</surname> <given-names>A</given-names></string-name>, <string-name><surname>Krahmer</surname> <given-names>N</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Immunity-related GTPase induces lipophagy to prevent excess hepatic lipid accumulation</article-title>. <source>J Hepatol</source> <year>2020</year>;<volume>73</volume>:<fpage>771</fpage>–<lpage>782</lpage>.</mixed-citation></ref>
<ref id="c101"><label>101.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Peng</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Zeng</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Wan</surname> <given-names>L</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>GP73 is a TBC-domain Rab GTPase-activating protein contributing to the pathogenesis of non-alcoholic fatty liver disease without obesity</article-title>. <source>Nat Commun</source> <year>2021</year>;<volume>12</volume>:<fpage>7004</fpage>.</mixed-citation></ref>
<ref id="c102"><label>102.</label><mixed-citation publication-type="preprint"><person-group person-group-type="author"><string-name><surname>Agarwal</surname> <given-names>H</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Ozcan</surname> <given-names>L.</given-names></string-name></person-group> <article-title>Rap1 Activation Protects Against Fatty Liver and Non-Alcoholic Steatohepatitis Development</article-title>. <source>bioRxiv</source>. <year>2023</year>:DOI <pub-id pub-id-type="doi">10.1101/2023.10.24.563728</pub-id>.</mixed-citation></ref>
<ref id="c103"><label>103.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Castane</surname> <given-names>H</given-names></string-name>, <string-name><surname>Jimenez-Franco</surname> <given-names>A</given-names></string-name>, <string-name><surname>Hernandez-Aguilera</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Multi-omics profiling reveals altered mitochondrial metabolism in adipose tissue from patients with metabolic dysfunction-associated steatohepatitis</article-title>. <source>EBioMedicine</source> <year>2025</year>;<volume>111</volume>:<fpage>105532</fpage>.</mixed-citation></ref>
<ref id="c104"><label>104.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Raverdy</surname> <given-names>V</given-names></string-name>, <string-name><surname>Tavaglione</surname> <given-names>F</given-names></string-name>, <string-name><surname>Chatelain</surname> <given-names>E</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease</article-title>. <source>Nat Med</source> <year>2024</year>;<volume>30</volume>:<fpage>3624</fpage>–<lpage>3633</lpage>.</mixed-citation></ref>
<ref id="c105"><label>105.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chalasani</surname> <given-names>N</given-names></string-name>, <string-name><surname>Younossi</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Lavine</surname> <given-names>JE</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases</article-title>. <source>Hepatology</source> <year>2017</year>;<volume>67</volume>:<fpage>328</fpage>–<lpage>357</lpage>.</mixed-citation></ref>
<ref id="c106"><label>106.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Saunders</surname> <given-names>JB</given-names></string-name>, <string-name><surname>Aasland</surname> <given-names>OG</given-names></string-name>, <string-name><surname>Babor</surname> <given-names>TF</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II</article-title>. <source>Addiction</source> <year>1993</year>;<volume>88</volume>:<fpage>791</fpage>–<lpage>804</lpage>.</mixed-citation></ref>
<ref id="c107"><label>107.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brunt</surname> <given-names>EM</given-names></string-name>, <string-name><surname>Kleiner</surname> <given-names>DE</given-names></string-name>, <string-name><surname>Wilson</surname> <given-names>LA</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings</article-title>. <source>Hepatology</source> <year>2011</year>;<volume>53</volume>:<fpage>810</fpage>–<lpage>20</lpage>.</mixed-citation></ref>
<ref id="c108"><label>108.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kleiner</surname> <given-names>DE</given-names></string-name>, <string-name><surname>Brunt</surname> <given-names>EM</given-names></string-name>, <string-name><surname>Van Natta</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Design and validation of a histological scoring system for nonalcoholic fatty liver disease</article-title>. <source>Hepatology</source> <year>2005</year>;<volume>41</volume>:<fpage>1313</fpage>–<lpage>21</lpage>.</mixed-citation></ref>
<ref id="c109"><label>109.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wu</surname> <given-names>ZE</given-names></string-name>, <string-name><surname>Kruger</surname> <given-names>MC</given-names></string-name>, <string-name><surname>Cooper</surname> <given-names>GJS</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Tissue-Specific Sample Dilution: An Important Parameter to Optimise Prior to Untargeted LC-MS Metabolomics</article-title>. <source>Metabolites</source> <year>2019</year>;<volume>9</volume>:<fpage>124</fpage>.</mixed-citation></ref>
<ref id="c110"><label>110.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xu</surname> <given-names>J</given-names></string-name>, <string-name><surname>Begley</surname> <given-names>P</given-names></string-name>, <string-name><surname>Church</surname> <given-names>SJ</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Graded perturbations of metabolism in multiple regions of human brain in Alzheimer’s disease: Snapshot of a pervasive metabolic disorder</article-title>. <source>Biochim Biophys Acta</source> <year>2016</year>;<volume>1862</volume>:<fpage>1084</fpage>–<lpage>92</lpage>.</mixed-citation></ref>
<ref id="c111"><label>111.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lee</surname> <given-names>DY</given-names></string-name>, <string-name><surname>Kind</surname> <given-names>T</given-names></string-name>, <string-name><surname>Yoon</surname> <given-names>YR</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Comparative evaluation of extraction methods for simultaneous mass-spectrometric analysis of complex lipids and primary metabolites from human blood plasma</article-title>. <source>Anal Bioanal Chem</source> <year>2014</year>;<volume>406</volume>:<fpage>7275</fpage>–<lpage>86</lpage>.</mixed-citation></ref>
<ref id="c112"><label>112.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Narayanaswamy</surname> <given-names>P</given-names></string-name>, <string-name><surname>Teo</surname> <given-names>G</given-names></string-name>, <string-name><surname>Ow</surname> <given-names>JR</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>MetaboKit: a comprehensive data extraction tool for untargeted metabolomics</article-title>. <source>Mol Omics</source> <year>2020</year>;<volume>16</volume>:<fpage>436</fpage>–<lpage>447</lpage>.</mixed-citation></ref>
    <ref id="c113"><label>113.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Gene Ontology Consortium</collab>, <string-name><surname>Aleksander</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Balhoff</surname> <given-names>J</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>The Gene Ontology knowledgebase in 2023</article-title>. <source>Genetics</source> <year>2023</year>;<volume>224</volume>:<fpage>iyad031</fpage>.</mixed-citation></ref>
<ref id="c114"><label>114.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bindea</surname> <given-names>G</given-names></string-name>, <string-name><surname>Mlecnik</surname> <given-names>B</given-names></string-name>, <string-name><surname>Hackl</surname> <given-names>H</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks</article-title>. <source>Bioinformatics</source> <year>2009</year>;<volume>25</volume>:<fpage>1091</fpage>–<lpage>3</lpage>.</mixed-citation></ref>
<ref id="c115"><label>115.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kanehisa</surname> <given-names>M</given-names></string-name>, <string-name><surname>Sato</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Kawashima</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>KEGG as a reference resource for gene and protein annotation</article-title>. <source>Nucleic Acids Res</source> <year>2016</year>;<volume>44</volume>:<fpage>D457</fpage>–<lpage>62</lpage>.</mixed-citation></ref>
<ref id="c116"><label>116.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Otasek</surname> <given-names>D</given-names></string-name>, <string-name><surname>Morris</surname> <given-names>JH</given-names></string-name>, <string-name><surname>Boucas</surname> <given-names>J</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Cytoscape Automation: empowering workflow-based network analysis</article-title>. <source>Genome Biol</source> <year>2019</year>;<volume>20</volume>:<fpage>185</fpage>.</mixed-citation></ref>
<ref id="c117"><label>117.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhou</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>B</given-names></string-name>, <string-name><surname>Pache</surname> <given-names>L</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Metascape provides a biologist-oriented resource for the analysis of systems-level datasets</article-title>. <source>Nat Commun</source> <year>2019</year>;<volume>10</volume>:<fpage>1523</fpage>.</mixed-citation></ref>
</ref-list>
</back>
<sub-article id="sa0" article-type="editor-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.109534.1.sa3</article-id>
<title-group>
<article-title>eLife Assessment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Seldin</surname>
<given-names>Marcus M</given-names>
</name>
<role specific-use="editor">Reviewing Editor</role>
<aff>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/04gyf1771</institution-id><institution>University of California, Irvine</institution>
</institution-wrap>
<city>Irvine</city>
<country>United States of America</country>
</aff>
</contrib>
</contrib-group>
<kwd-group kwd-group-type="evidence-strength">
<kwd>Solid</kwd>
</kwd-group>
<kwd-group kwd-group-type="claim-importance">
<kwd>Useful</kwd>
</kwd-group>
</front-stub>
<body>
<p>The authors provide a <bold>useful</bold> integrated analytical approach to investigating MASLD focused on diverse multiomic integration methods. The strength of evidence for this new resource is <bold>solid</bold>, as analyses highlight the importance of previously-described pathophysiologic processes, as well as unveil several new mechanisms as key features of MASLD in obese patients.</p>
</body>
</sub-article>
<sub-article id="sa1" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.109534.1.sa2</article-id>
<title-group>
<article-title>Reviewer #1 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) ranges from simple steatosis, steatohepatitis, fibrosis/cirrhosis, and hepatocellular carcinoma. In the current study, the authors aimed to determine the early molecular signatures differentiating patients with MASLD associated fibrosis from those patients with early MASLD but no symptoms. The authors recruited 109 obese individuals before bariatric surgery. They separated the cohorts as no MASLD (without histological abnormalities) and MASLD. The liver samples were then subjected to transcriptomic and metabolomic analysis. The serum samples were subjected to metabolomic analysis. The authors identified dysregulated lipid metabolism, including glyceride lipids, in the liver samples of MASLD patients compared to the no MASLD ones. Circulating metabolomic changes in lipid profiles slightly correlated with MASLD, possibly due to the no MASLD samples derived from obese patients. Several genes involved in lipid droplet formation were also found elevated in MASLD patients. Besides, elevated levels of amino acids, which are possibly related to collagen synthesis, were observed in MASLD patients. Several antioxidant metabolites were increased in MASLD patients. Furthermore, dysregulated genes involved in mitochondrial function and autophagy were identified in MASLD patients, likely linking oxidative stress to MASLD progression. The authors then determined the representative gene signatures in the development of fibrosis by comparing this cohort with the other two published cohorts. Top enriched pathways in fibrotic patients included GTPas signaling and innate immune responses, suggesting the involvement of GTPas in MASLD progression to fibrosis. The authors then challenged human patient derived 3D spheroid system with a dual PPARa/d agonist and found that this treatment restored the expression levels of GTPase-related genes in MASLD 3D spheroids. In conclusion, the authors suggested the involvement of upregulated GTPase-related genes during fibrosis initiation.</p>
<p>Concerns from first round of review:</p>
<p>(1) A recent study, via proteomic and transcriptomic analysis, revealed that four proteins (ADAMTSL2, AKR1B10, CFHR4 and TREM2) could be used to identify MASLD patients at risk of steatohepatitis (PMID: 37037945). It is not clear why the authors did not include this study in their comparison.</p>
<p>(2) The authors recruited 109 patients but only performed transcriptomic and metabolomic analysis in 94 liver samples. Why did the authors exclude other samples?</p>
<p>(3) The authors mentioned clinical data in Table 1 but did not present the table in this manuscript.</p>
<p>(4) The generated metabolomic data could be a very useful resource to the MASLD community. However, it is very confusing how the data was generated in those supplemental tables. There is no clear labeling of human clinical information in those tables. Also, what do those values mean in columns 47-154? This reviewer assumed that they are the raw data of metabolomic analysis in plasma samples. However, without clear clinical information in these patients, it is impossible that any scientist can use the data to reproduce the authors' findings.</p>
<p>(5) In Fig. 5B, the authors excluded the steatosis and fibrosis overlapped genes. Steatosis and fibrosis specific genes could simply reflect the outcomes rather than causes. In this case, the obtained results might not identify the gene signatures related to fibrosis initiation.</p>
<p>(6 In Fig. 6D, the authors used 3D liver spheroid to validate their findings. However, there is no images showing the 3D liver spheroid formation before and after PPARa/d agonist treatment. It is not clear whether the 3D liver spheroid was successfully established.</p>
<p>(7) The authors suggested that targeting LX-2 cells with Rac1 and Cdc42 inhibitors could reduce collagen production. Did the authors observe these two genes upregulated in mRNA and protein expression levels in their cohort when compared MASLD patients with and without fibrosis?</p>
<p>(8) Did the authors observe that the expression levels of Rac1 and Cdc42 are correlated with fibrosis progression in MASLD patients?</p>
<p>(9) Other studies have revealed several metabolite changes related to MASLD progression (PMID: 35434590, PMID: 22364559). However, the authors did not discuss the discrepancies between their findings with the previous studies.</p>
<p>Significance:</p>
<p>Overall, the current study might provide some new resources regarding transcriptomic and metabolomic data derived from obese patients with and without MASLD. The MASLD research community will be interested in the resource data.</p>
<p>Comments on revised version:</p>
<p>Thank you for the authors' responses to my concerns. I do not have any further comments.</p>
</body>
</sub-article>
<sub-article id="sa2" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.109534.1.sa1</article-id>
<title-group>
<article-title>Reviewer #2 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>In this paper, Kaldis and collaborators investigate the molecular heterogeneity of a 109 morbidly obese patient cohort, focusing on liver transcriptomics and metabolomics analysis from liver and serum. The main finding (i.e. upregulation of GTPase-coding genes) was validated in spheroids and a human HSC cell line. As these proteins are involved in critical cellular functions related to metabolism and cytoskeleton dynamics, these findings shed light on their involvement in human liver pathology which so far has been poorly (or even not) documented to date. This is an interesting addition to the current knowledge about chronic liver pathology and warranting further in-depth molecular investigations to address molecular mechanisms of action (cellular specificity, GTPase-driven pathways...).</p>
<p>Strengths:</p>
<p>Using a well-characterized patient cohort of moderate size, the study provide transcriptomic and metabolomic data of high quality with adequate statistical corrections which are a very useful resource for the community. Mechanistic experiments usefully hint at novel druggable targets in the early steps of fibrosis, hence probably in hepatic stellate cell activation.</p>
<p>Weaknesses:</p>
<p>Cross comparisons with other cohorts is informative but of limited interest due to patient classification issues, inherent to histological staging practices. The lack of correlation between transcriptomic and metabolomic data is deceptive but expected due to the systemic nature of metabolomic analysis and was also observed in recently published papers.</p>
<p>Comments on revised version:</p>
<p>I have no further comment about this amended version, aside from suggesting to add (if known) the time at which biopsies were collected. Time-of-day is an important yet often overlooked parameter of gene expression variation, and along the same line, the imposed fasting to bariatric surgery patients is also a matter of variation of gene expression and of metabolite abundance. It is hoped that future investigations will more precisely characterize the role of the newly identified targets in MASLD.</p>
</body>
</sub-article>
<sub-article id="sa3" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.109534.1.sa0</article-id>
<title-group>
<article-title>Reviewer #3 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>Metabolic dysfunction associated liver disease (MASLD) describes a spectrum of progressive liver pathologies linked to life style-associated metabolic alterations (such as increased body weight and elevated blood sugar levels), reaching from steatosis over steatohepatitis to fibrosis and finally end stage complications, such as liver failure and hepatocellular carcinoma. Treatment options for MASLD include diet adjustments, weight loss, and the receptor-β (THR-β) agonist resmetirom, but remain limited at this stage, motivating further studies to elucidate molecular disease mechanisms to identify novel therapeutic targets.</p>
<p>In their present study, the authors aim to identify early molecular changes in MASLD linked to obesity. To this end, they study a cohort of 109 obese individuals with no or early-stage MASLD combining measurements from two anatomic sides: 1. bulk RNA-sequencing and metabolomics of liver biopsies, and 2. metabolomics from patient blood. Their major finding is that GTPase-related genes are transcriptionally altered in livers of individuals with steatosis with fibrosis compared to steatosis without fibrosis.</p>
<p>Comments from the first round of review:</p>
<p>(1) Confounders (such as (pre-)diabetes)</p>
<p>The patient table shows significant differences in non-MASLD vs. MASLD individuals, with the latter suffering more often from diabetes or hypertriglyceridemia. Rather than just stating corrections, subgroup analyses should be performed (accompanied with designated statistical power analyses) to infer the degree to which these conditions contribute to the observations. I.e., major findings stating MASLD-associated changes should hold true in the subgroup of MASLD patients without diabetes/of female sex and so forth (testing for each of the significant differences between groups).</p>
<p>Post-rebuttal update: The authors have performed the requested sub-group analysis and find the gene signatures hold for the non-diabetic sub-cohort, but not the diabetic subgroup. They denote a likely interaction between fibrosis and diabetes, that was not corrected for in the original analysis.</p>
<p>(2) External validation</p>
<p>Additionally, to back up the major GTPase signature findings, it would be desirable to analyze an external dataset of (pre)diabetes patients (other biased groups) for alternations in these genes. It would be important to know if this signature also shows in non-MASLD diabetic patients vs. healthy patients or is a feature specific to MASLD. Also, could the matched metabolic data be used to validate metabolite alterations that would be expected under GTPase-associated protein dysregulation?</p>
<p>Post-rebuttal update: The authors confirm that with the present data, insulin resistance cannot be fully ruled out as a confounder to the GTP-ase related gene signature. They however plan future mouse model experiments to study whether the GTPase-fibrosis signature differs in diabetic vs. non-diabetic conditions.</p>
<p>(3).3D liver spheroid MASH model, Fig. 6D/E</p>
<p>This 3D experiment is technically not an external validation of GTPase-related genes being involved in MASLD, since patient-derived cells may only retain changes that have happened in vivo. To demonstrate that the GTPase expression signature is specifically invoked by fibrosis the LX-2 set up is more convincing, however, the up-regulation of the GTPase-related genes upon fibrosis induction with TGF-beta, in concordance with the patient data, needs to be shown first (qPCR or RNA-seq). Additionally, the description of the 3D model is too uncritical. The maintenance of functional PHHs is a major challenge (PMID: 38750036, PMID: 21953633, PMID: 40240606, PMID: 31023926). It cannot be ruled out that their findings are largely attributable to either 1) the (other present) mesenchymal cells (i.e., mesenchyme-derived cells, such as for example hepatic stellate cells, not to be confused with mesenchymal stem cells, MSCs), or 2) related to potential changes in PHHs in culture, and these limitations need to be stated.</p>
<p>Post-rebuttal update: To address the concern of other cells than hepatocytes contributing to the observed effects in culture, the authors performed TGF-beta treatment in independent mono-cultures (Figure R4): LX-2 and hepatocytes, and the spheroid system. Surprisingly, important genes highlighted in Figure 6E for the spheroid system (RAB6A, ARL4A, RAB27B, DIRAS2) are all absent from this qPCR(?) validation experiment. The authors evaluate instead RAC1, RHOU, VAV1, DOCK2, RAB32. ­In spheroids, RHOU and RAB32 are down-regulated with TGF-B. In hepatocytes DOCK2 and RAC seemed up-regulated. They find no difference in these genes in LX-2 cells. Surprisingly, ACTA2 expression values are missing for LX-2 cells. Together, it is hard to judge which individual cell type recapitulates the changes observed in patients in this validation experiment, as the major genes called out in Figure 6E are not analyzed.</p>
<p>Unfortunately, the 3D liver spheroid model used (as presente­d in PMID39605182) lacks important functional validation tests of maintained hepatocyte identity in culture (at the very least Albumin expression and secretion plus CYP3A4 assay). This functional data (acquired at the time point in culture when the RNA expression analysis in 6E was performed) is indispensable prior to stating that mature hepatocytes cause the observed effects.</p>
<p>(4) Novelty / references</p>
<p>Similar studies that also combined liver and blood lipidomics/metabolomics in obese individuals with and without MASLD (e.g. PMID 39731853, 39653777) should be cited. Additionally, it would benefit the quality of the discussion to state how findings in this study add new insights over previous studies, if their findings/insights differ, and if so, why.</p>
<p>Post-rebuttal update: The authors have included the studies into their discussion.</p>
</body>
</sub-article>
</article>